US20140080763A1 - N-carboxyalkylauristatins and use thereof - Google Patents
N-carboxyalkylauristatins and use thereof Download PDFInfo
- Publication number
- US20140080763A1 US20140080763A1 US14/004,699 US201214004699A US2014080763A1 US 20140080763 A1 US20140080763 A1 US 20140080763A1 US 201214004699 A US201214004699 A US 201214004699A US 2014080763 A1 US2014080763 A1 US 2014080763A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- stands
- formula
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims abstract description 147
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 161
- -1 propene-1,3-diyl Chemical group 0.000 claims description 86
- 150000003839 salts Chemical class 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 239000012453 solvate Substances 0.000 claims description 29
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 239000012442 inert solvent Substances 0.000 claims description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000004504 1,2,4-oxadiazolyl group Chemical class 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical class 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 125000002883 imidazolyl group Chemical class 0.000 claims description 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical class 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 108010059074 monomethylauristatin F Proteins 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 12
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 abstract description 11
- 108010093470 monomethyl auristatin E Proteins 0.000 abstract description 10
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract description 3
- 238000009097 single-agent therapy Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000002491 angiogenic effect Effects 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 description 85
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 238000004128 high performance liquid chromatography Methods 0.000 description 53
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 43
- 239000000203 mixture Substances 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 239000000243 solution Substances 0.000 description 36
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 30
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 29
- 239000003480 eluent Substances 0.000 description 28
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 27
- 0 *N(C)[C@H](C(=O)C[C@H](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)C(C)C)C(C)C Chemical compound *N(C)[C@H](C(=O)C[C@H](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)C(C)C)C(C)C 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical compound OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 description 20
- 125000006239 protecting group Chemical group 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 17
- 235000019253 formic acid Nutrition 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000005859 coupling reaction Methods 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000000825 ultraviolet detection Methods 0.000 description 11
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- VBLMLZLMVRYBOT-ZULUKCPQSA-N (2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(O)=O VBLMLZLMVRYBOT-ZULUKCPQSA-N 0.000 description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 108010044540 auristatin Proteins 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 238000004896 high resolution mass spectrometry Methods 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 6
- 230000006806 disease prevention Effects 0.000 description 6
- 210000004688 microtubule Anatomy 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000000562 conjugate Substances 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000010931 ester hydrolysis Methods 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LNEHHTWYEBGHBY-OUAUKWLOSA-N (2r,3r)-3-methoxy-2-methyl-3-[(2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]propanoic acid Chemical compound OC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)OC(C)(C)C LNEHHTWYEBGHBY-OUAUKWLOSA-N 0.000 description 3
- JXVUEVNIKJJONX-LPQFERQCSA-N (e,2s)-1,4-diphenylbut-3-en-2-amine Chemical compound C([C@H](N)\C=C\C=1C=CC=CC=1)C1=CC=CC=C1 JXVUEVNIKJJONX-LPQFERQCSA-N 0.000 description 3
- JXVUEVNIKJJONX-YUQCYMQKSA-N (z,2s)-1,4-diphenylbut-3-en-2-amine Chemical compound C([C@H](N)\C=C/C=1C=CC=CC=1)C1=CC=CC=C1 JXVUEVNIKJJONX-YUQCYMQKSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- DANMYZFPINRVPJ-JSTLMPQBSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C DANMYZFPINRVPJ-JSTLMPQBSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- 108010074604 Epoetin Alfa Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000007257 deesterification reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
- JMHCCAYJTTWMCX-QWPJCUCISA-M sodium;(2s)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 JMHCCAYJTTWMCX-QWPJCUCISA-M 0.000 description 3
- 229960003787 sorafenib Drugs 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- NBLWRFNWDBPHKB-FSDCSDTHSA-N tert-butyl (3r,4s,5s)-4-[[(2s)-2-amino-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoate Chemical compound CC(C)[C@H](N)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)OC(C)(C)C)OC NBLWRFNWDBPHKB-FSDCSDTHSA-N 0.000 description 3
- ZJTYRNPLVNMVPQ-LBPRGKRZSA-N tert-butyl n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)CC1=CC=CC=C1 ZJTYRNPLVNMVPQ-LBPRGKRZSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- WQVMMOHOCDYLGP-PFEQFJNWSA-N (1r)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@@H](N)C=1OC(=NN=1)C=1C=CC=CC=1)C1=CC=CC=C1 WQVMMOHOCDYLGP-PFEQFJNWSA-N 0.000 description 2
- WQVMMOHOCDYLGP-UQKRIMTDSA-N (1s)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethanamine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@H](N)C=1OC(=NN=1)C=1C=CC=CC=1)C1=CC=CC=C1 WQVMMOHOCDYLGP-UQKRIMTDSA-N 0.000 description 2
- RGMLBDDJOQIWAS-INIZCTEOSA-N (2s)-1-benzylsulfanyl-3-phenylpropan-2-amine Chemical compound C([C@@H](N)CC=1C=CC=CC=1)SCC1=CC=CC=C1 RGMLBDDJOQIWAS-INIZCTEOSA-N 0.000 description 2
- FKTZTXDZFKDYFB-INIZCTEOSA-N (2s)-1-benzylsulfonyl-3-phenylpropan-2-amine Chemical compound C([C@H](N)CS(=O)(=O)CC=1C=CC=CC=1)C1=CC=CC=C1 FKTZTXDZFKDYFB-INIZCTEOSA-N 0.000 description 2
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 2
- CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 2
- SMVBIYSFDNRJJI-FCUBIXSHSA-N (3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@H]([C@@H](CC(O)=O)OC)[C@@H](C)CC)C(C)C)C3=CC=CC=C3C2=C1 SMVBIYSFDNRJJI-FCUBIXSHSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- GIKKLCOINYFDKM-GCTZUXDNSA-N (z,2s)-1,5-diphenylpent-3-en-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@H](N)\C=C/CC=1C=CC=CC=1)C1=CC=CC=C1 GIKKLCOINYFDKM-GCTZUXDNSA-N 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- LGEXGKUJMFHVSY-UHFFFAOYSA-N 2-n,4-n,6-n-trimethyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(NC)=NC(NC)=N1 LGEXGKUJMFHVSY-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- HFEKDTCAMMOLQP-RRKCRQDMSA-N 5-fluorodeoxyuridine monophosphate Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C(F)=C1 HFEKDTCAMMOLQP-RRKCRQDMSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- DAAHBNBYJGIHNQ-DMPXWKOKSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C DAAHBNBYJGIHNQ-DMPXWKOKSA-N 0.000 description 2
- BCGUVGJQTTWGMP-KQGBVCDZSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCC(=O)O)C(C)C Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCC(=O)O)C(C)C BCGUVGJQTTWGMP-KQGBVCDZSA-N 0.000 description 2
- ZGFPHMQCIOBMDV-YRFBTPSQSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCC(=O)OC)C(C)C Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCC(=O)OC)C(C)C ZGFPHMQCIOBMDV-YRFBTPSQSA-N 0.000 description 2
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 231100000777 Toxicophore Toxicity 0.000 description 2
- GITITJADGZYSRL-UHFFFAOYSA-N [H]C(=C)CC(=O)OC Chemical compound [H]C(=C)CC(=O)OC GITITJADGZYSRL-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 229960000605 dexrazoxane Drugs 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960000452 diethylstilbestrol Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229930013356 epothilone Natural products 0.000 description 2
- 150000003883 epothilone derivatives Chemical class 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960000961 floxuridine Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- 229960001751 fluoxymesterone Drugs 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960004635 mesna Drugs 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- SPMFGGXNLGFMOL-JECZLZBHSA-N methyl 4-[(e,3s)-3-amino-4-phenylbut-1-enyl]benzoate;2,2,2-trifluoroacetic acid Chemical class OC(=O)C(F)(F)F.C1=CC(C(=O)OC)=CC=C1\C=C\[C@@H](N)CC1=CC=CC=C1 SPMFGGXNLGFMOL-JECZLZBHSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Inorganic materials [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JRXGCIIOQALIMZ-LWEGJDAASA-N tert-butyl (3r,4s,5s)-3-methoxy-5-methyl-4-(methylamino)heptanoate;hydrochloride Chemical compound Cl.CC[C@H](C)[C@H](NC)[C@H](OC)CC(=O)OC(C)(C)C JRXGCIIOQALIMZ-LWEGJDAASA-N 0.000 description 2
- SXCDYMWHVBJDJZ-ZXHYAQOVSA-N tert-butyl (3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]heptanoate Chemical compound CC(C)(C)OC(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 SXCDYMWHVBJDJZ-ZXHYAQOVSA-N 0.000 description 2
- JJTGKUKIKMQVDD-SPEVZLOGSA-N tert-butyl (3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoate Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@H](C(=O)N(C)[C@H]([C@@H](CC(=O)OC(C)(C)C)OC)[C@@H](C)CC)C(C)C)C3=CC=CC=C3C2=C1 JJTGKUKIKMQVDD-SPEVZLOGSA-N 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 229960004824 triptorelin Drugs 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-VXNVDRBHSA-N (+)-norephedrine Chemical compound C[C@@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-VXNVDRBHSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- SDUJPRHHSGPXFP-ZPQOTBKHSA-N (2r,3s)-2-methoxy-2-methyl-4-phenyl-3-[(2s)-pyrrolidin-2-yl]butanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@H]([C@@](C)(OC)C(O)=O)[C@H]1NCCC1)C1=CC=CC=C1 SDUJPRHHSGPXFP-ZPQOTBKHSA-N 0.000 description 1
- YCXXXPZNQXXRIG-IBGZPJMESA-N (2s)-2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N(C)[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 YCXXXPZNQXXRIG-IBGZPJMESA-N 0.000 description 1
- VESKBLGTHHPZJF-QNWVGRARSA-N (2s)-2-amino-5-[[(2r)-2-amino-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]propanoyl]-[(r)-carboxy(phenyl)methyl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](N)C(=O)N(C(=O)CC[C@H](N)C(O)=O)[C@@H](C(O)=O)C1=CC=CC=C1 VESKBLGTHHPZJF-QNWVGRARSA-N 0.000 description 1
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 1
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- JILHZKWLEAKYRC-UHFFFAOYSA-N 1-methoxy-2,2-dimethylpropane Chemical compound COCC(C)(C)C JILHZKWLEAKYRC-UHFFFAOYSA-N 0.000 description 1
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- JCJODSMQBXMELN-UHFFFAOYSA-N 2-ethyl-5-phenyl-1,2-oxazol-2-ium Chemical compound O1[N+](CC)=CC=C1C1=CC=CC=C1 JCJODSMQBXMELN-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- MPSXGPCFLAGJOM-UHFFFAOYSA-M 2-tert-butyl-5-methyl-1,2-oxazol-2-ium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1=CC=[N+](C(C)(C)C)O1 MPSXGPCFLAGJOM-UHFFFAOYSA-M 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- DBVTYDLZMXNRIN-UHFFFAOYSA-N 3-benzyl-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1CC1=CC=CC=C1 DBVTYDLZMXNRIN-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- HVIXPSKQLBOEGZ-GYRSRQGASA-N 4-[[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(2-phenylethylamino)propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-methylamino]butanoic acid Chemical compound OC(=O)CCCN(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 HVIXPSKQLBOEGZ-GYRSRQGASA-N 0.000 description 1
- CEKFXXKYKOMVEX-MGRFWBRLSA-N 4-[[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl Chemical compound OC(=O)CCCN(C)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 CEKFXXKYKOMVEX-MGRFWBRLSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- JDOCMQKOZIVOND-QMMMGPOBSA-N CC(=O)[C@H](C(C)C)N(C)C Chemical compound CC(=O)[C@H](C(C)C)N(C)C JDOCMQKOZIVOND-QMMMGPOBSA-N 0.000 description 1
- ORDQDMABOABJGM-SQCIYPPQSA-N CC(C)[C@@H](C(=O)O)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.CC[C@H](C(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](N)C(C)C.CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC(C)(C)C)OC.CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)O Chemical compound CC(C)[C@@H](C(=O)O)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2.CC[C@H](C(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](N)C(C)C.CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC(C)(C)C)OC.CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)O ORDQDMABOABJGM-SQCIYPPQSA-N 0.000 description 1
- ZGGSWCAVFZPALE-ATZCPNFKSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1 Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1 ZGGSWCAVFZPALE-ATZCPNFKSA-N 0.000 description 1
- FHFIIQUMHOAPIE-SGMGOOAPSA-N CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)OC(C)(C)C Chemical compound CCC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)OC(C)(C)C FHFIIQUMHOAPIE-SGMGOOAPSA-N 0.000 description 1
- NLGBXIHOWLQOKV-MPTYRVRUSA-N CC[C@H](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)OC)OC)C(C)C Chemical compound CC[C@H](C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)OC)OC)C(C)C NLGBXIHOWLQOKV-MPTYRVRUSA-N 0.000 description 1
- KNCSWJHMGRXEDN-QMMMGPOBSA-N CC[C@H](C(C)=O)C(C)C Chemical compound CC[C@H](C(C)=O)C(C)C KNCSWJHMGRXEDN-QMMMGPOBSA-N 0.000 description 1
- QGAFVPQJWWMKRM-YDQVIEGPSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C QGAFVPQJWWMKRM-YDQVIEGPSA-N 0.000 description 1
- GPFQFBDVXTYWRJ-MSASFIIASA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C GPFQFBDVXTYWRJ-MSASFIIASA-N 0.000 description 1
- ZCYWWUBFGZJBAR-CVHSMXKTSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C ZCYWWUBFGZJBAR-CVHSMXKTSA-N 0.000 description 1
- QNZLZLPQXZDKCX-ZLUWYREFSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C QNZLZLPQXZDKCX-ZLUWYREFSA-N 0.000 description 1
- IOBTUFQLHKQRTN-IXFVIMRFSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)CCCC1=CNC2=C1C=CC=C2)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C IOBTUFQLHKQRTN-IXFVIMRFSA-N 0.000 description 1
- IYSYTFMHAUEZLY-HMMXMGSASA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C IYSYTFMHAUEZLY-HMMXMGSASA-N 0.000 description 1
- VBXPYIWKUUUCES-LPADVAFFSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C VBXPYIWKUUUCES-LPADVAFFSA-N 0.000 description 1
- RDOYOGHCLNBVLV-FPQRQJQOSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C RDOYOGHCLNBVLV-FPQRQJQOSA-N 0.000 description 1
- RWXMNNZETXUSGN-JAQONJBJSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C RWXMNNZETXUSGN-JAQONJBJSA-N 0.000 description 1
- DMJPXZLWHNCHGY-QFQZVOHJSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@@H](CC1=CC=CC=C1)CS(=O)(=O)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C DMJPXZLWHNCHGY-QFQZVOHJSA-N 0.000 description 1
- WECZRDPALJQCCF-HGRUVCFJSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)O)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)O)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C WECZRDPALJQCCF-HGRUVCFJSA-N 0.000 description 1
- GAFOCRJKUMSXFX-TVMCXUNLSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C GAFOCRJKUMSXFX-TVMCXUNLSA-N 0.000 description 1
- LOWNUJPUHLVYOK-KUNVIGNCSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(=O)OC)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C LOWNUJPUHLVYOK-KUNVIGNCSA-N 0.000 description 1
- XWLIHQFOALAXBI-BWKPDQMDSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(C)=O)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=C(C(C)=O)C=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C XWLIHQFOALAXBI-BWKPDQMDSA-N 0.000 description 1
- BKKRIMGCXWOSHR-FXTLCWSQSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C BKKRIMGCXWOSHR-FXTLCWSQSA-N 0.000 description 1
- WBSABYYVDIDSQJ-HBCBIUJASA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C/C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C WBSABYYVDIDSQJ-HBCBIUJASA-N 0.000 description 1
- BKKRIMGCXWOSHR-ANKJXZIBSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C BKKRIMGCXWOSHR-ANKJXZIBSA-N 0.000 description 1
- WBSABYYVDIDSQJ-ULQAIMHDSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\C1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C WBSABYYVDIDSQJ-ULQAIMHDSA-N 0.000 description 1
- KDJJDLWZQWHJRR-QJNBUPEVSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C KDJJDLWZQWHJRR-QJNBUPEVSA-N 0.000 description 1
- RAQZDINEYJGPIW-NAQVUXOWSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C RAQZDINEYJGPIW-NAQVUXOWSA-N 0.000 description 1
- JDLBXCXUXKUMQZ-XSUDOCASSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](C)[C@@H](O)C1=CC=CC=C1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C JDLBXCXUXKUMQZ-XSUDOCASSA-N 0.000 description 1
- IYSYTFMHAUEZLY-RJUBTVCWSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C IYSYTFMHAUEZLY-RJUBTVCWSA-N 0.000 description 1
- VBXPYIWKUUUCES-IFDSYWDYSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)C[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C VBXPYIWKUUUCES-IFDSYWDYSA-N 0.000 description 1
- IHOZWSIDLQEDIH-QYRMEXCASA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C IHOZWSIDLQEDIH-QYRMEXCASA-N 0.000 description 1
- YAQPWNHGAQKBEH-BHJLFUCHSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C.CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)OCC1=CC=CC=C1.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](CC)C(C)C)C(C)C.[3H]N Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C.CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)OCC1=CC=CC=C1.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](CC)C(C)C)C(C)C.[3H]N YAQPWNHGAQKBEH-BHJLFUCHSA-N 0.000 description 1
- CIEVFIBAOITBQR-PONLZESJSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CO[C@@H]([C@@H]1CCCN1C(=O)OC(C)(C)C)[C@@H](C)C(=O)O.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C.[3H]N.[3H]N Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C.CO[C@@H]([C@@H]1CCCN1C(=O)OC(C)(C)C)[C@@H](C)C(=O)O.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](NC)C(C)C)C(C)C.[3H]N.[3H]N CIEVFIBAOITBQR-PONLZESJSA-N 0.000 description 1
- IIYQMTGRFJQPBD-DDUDUBSGSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)OC)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)OC)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C IIYQMTGRFJQPBD-DDUDUBSGSA-N 0.000 description 1
- HTUIDCKCLGOXED-AWSJQEAXSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(C)=O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(C)=O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C HTUIDCKCLGOXED-AWSJQEAXSA-N 0.000 description 1
- IUVRXZDXPKHWFW-SNDTZCJISA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OC(C)(C)C)C(C)C IUVRXZDXPKHWFW-SNDTZCJISA-N 0.000 description 1
- OETCSAXXORQFRS-PGFJMRCZSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C OETCSAXXORQFRS-PGFJMRCZSA-N 0.000 description 1
- DBWWDAOXIRJLGO-PFMZIPKWSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](CC(=O)OCC1=CC=CC=C1)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](CC(=O)OCC1=CC=CC=C1)C(C)C DBWWDAOXIRJLGO-PFMZIPKWSA-N 0.000 description 1
- KHXVUKNJXZUFCV-VYWJWOJFSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)OC(C)(C)C)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C(=O)OCC1C2=C(C=CC=C2)C2=C1C=CC=C2)C(C)C KHXVUKNJXZUFCV-VYWJWOJFSA-N 0.000 description 1
- VLLNCCAWCCNYPH-CQRJNKKSSA-N CC[C@H](C)[C@@H]([C@@H](CC(=O)OC)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)OC)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C VLLNCCAWCCNYPH-CQRJNKKSSA-N 0.000 description 1
- YHXONGJJBZQRGQ-SMQUXOHWSA-N CC[C@H](C)[C@@H]([C@@H](CC(C)=O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(C)=O)OC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)C)C(C)C YHXONGJJBZQRGQ-SMQUXOHWSA-N 0.000 description 1
- VRBFIJCLCNKGGT-LOWVWBTDSA-N CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC(C)(C)C)OC Chemical compound CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC(C)(C)C)OC VRBFIJCLCNKGGT-LOWVWBTDSA-N 0.000 description 1
- FOMZTSOKUXLGCJ-NGZCFLSTSA-N CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC)OC Chemical compound CC[C@H](C)[C@H](NC)[C@@H](CC(=O)OC)OC FOMZTSOKUXLGCJ-NGZCFLSTSA-N 0.000 description 1
- PQICQDBGEQRQSV-XLNAKTSKSA-N COC(=O)C1=CC=C(/C=C/[C@@H](N)CC2=CC=CC=C2)C=C1 Chemical compound COC(=O)C1=CC=C(/C=C/[C@@H](N)CC2=CC=CC=C2)C=C1 PQICQDBGEQRQSV-XLNAKTSKSA-N 0.000 description 1
- WUNJYMIULWQVAH-HRDYMLBCSA-N COC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1 Chemical compound COC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1 WUNJYMIULWQVAH-HRDYMLBCSA-N 0.000 description 1
- ZAHRDPIWMGLOQJ-ZDUSSCGKSA-N CON(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)OC(C)(C)C Chemical compound CON(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)OC(C)(C)C ZAHRDPIWMGLOQJ-ZDUSSCGKSA-N 0.000 description 1
- RTVZDQKERARPAM-VHDGCEQUSA-N CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)OCC1=CC=CC=C1 Chemical compound CO[C@@H]([C@@H]1CCCN1)[C@@H](C)C(=O)OCC1=CC=CC=C1 RTVZDQKERARPAM-VHDGCEQUSA-N 0.000 description 1
- FWWHDWMPXGZEKY-WCFLWFBJSA-N CO[C@@H]([C@@H]1CCCN1C(=O)OC(C)(C)C)[C@@H](C)C(C)=O Chemical compound CO[C@@H]([C@@H]1CCCN1C(=O)OC(C)(C)C)[C@@H](C)C(C)=O FWWHDWMPXGZEKY-WCFLWFBJSA-N 0.000 description 1
- DDIRVGKIQBDTGV-VXNVDRBHSA-N C[C@H]([C@H](c1ccccc1)O)I Chemical compound C[C@H]([C@H](c1ccccc1)O)I DDIRVGKIQBDTGV-VXNVDRBHSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100039350 Interferon alpha-7 Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000408529 Libra Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- OVJXUELLYTXSHZ-AWEZNQCLSA-N N[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1 Chemical compound N[C@@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1 OVJXUELLYTXSHZ-AWEZNQCLSA-N 0.000 description 1
- SCMURDIUWTWPPG-KYTCBBFDSA-N N[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1 Chemical compound N[C@H](/C=C\CC1=CC=CC=C1)CC1=CC=CC=C1 SCMURDIUWTWPPG-KYTCBBFDSA-N 0.000 description 1
- OVJXUELLYTXSHZ-CQSZACIVSA-N N[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1 Chemical compound N[C@H](CC1=CC=CC=C1)C1=NN=C(C2=CC=CC=C2)O1 OVJXUELLYTXSHZ-CQSZACIVSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- VRSLTNZJOUZKLX-UHFFFAOYSA-N Ondansetron hydrochloride Chemical compound O.O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 VRSLTNZJOUZKLX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010029107 Respiratory Tract Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 108700011582 TER 286 Proteins 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 description 1
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 1
- SPUOQMILLLRZAM-XVHSGREMSA-N [3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](CC)C(C)C)C(C)C.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.[H]C(=C)CCOC=O Chemical compound [3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@@H](CC)C(C)C)C(C)C.[3H]CC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](CC(=O)[C@H](C(C)C)N(C)CCCC(=O)O)C(C)C.[H]C(=C)CCOC=O SPUOQMILLLRZAM-XVHSGREMSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 1
- 229950002421 acolbifene Drugs 0.000 description 1
- 229940099550 actimmune Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229940062334 aloprim Drugs 0.000 description 1
- 229940014175 aloxi Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940115115 aranesp Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- UVJYAKBJSGRTHA-ZCRGAIPPSA-N arglabin Chemical compound C1C[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(C)=CC[C@]32O[C@]31C UVJYAKBJSGRTHA-ZCRGAIPPSA-N 0.000 description 1
- UVJYAKBJSGRTHA-UHFFFAOYSA-N arglabin Natural products C1CC2C(=C)C(=O)OC2C2C(C)=CCC32OC31C UVJYAKBJSGRTHA-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229950003620 asoprisnil Drugs 0.000 description 1
- GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- GFBIDXMGFODOOY-YRYCYXPXSA-N benzyl (2r,3r)-3-methoxy-2-methyl-3-[(2s)-pyrrolidin-2-yl]propanoate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C([C@H](C)[C@@H](OC)[C@H]1NCCC1)OCC1=CC=CC=C1 GFBIDXMGFODOOY-YRYCYXPXSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- ZFLASALABLFSNM-QBOHGLHMSA-L carbanide;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-oc Chemical compound [CH3-].[Co+3].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ZFLASALABLFSNM-QBOHGLHMSA-L 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229950001357 celmoleukin Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229940107841 daunoxome Drugs 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940005558 delestrogen Drugs 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229940003382 depo-medrol Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229950001287 edotecarin Drugs 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229940053603 elitek Drugs 0.000 description 1
- 229940087477 ellence Drugs 0.000 description 1
- 229940108890 emend Drugs 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229950006835 eptaplatin Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940064258 estrace Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940098617 ethyol Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 229960004585 etidronic acid Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 229940084910 gliadel Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000012499 inoculation medium Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940080161 levothroid Drugs 0.000 description 1
- 229940080162 levoxyl Drugs 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Inorganic materials [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229940101513 menest Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- WRVLBJXFSHALRZ-FUVGGWJZSA-N methyl (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoate Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 WRVLBJXFSHALRZ-FUVGGWJZSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 229940003515 orapred Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940097097 pediapred Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950007649 ranpirnase Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000008946 renal pelvis neoplasm Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229940063635 salagen Drugs 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229950009921 seocalcitol Drugs 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 108700022137 serine(71)- interleukin-1 beta Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940087854 solu-medrol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940084642 strontium-89 chloride Drugs 0.000 description 1
- AHBGXTDRMVNFER-FCHARDOESA-L strontium-89(2+);dichloride Chemical compound [Cl-].[Cl-].[89Sr+2] AHBGXTDRMVNFER-FCHARDOESA-L 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940099268 synthroid Drugs 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950001699 teceleukin Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- VZIUJIWPLDAAGJ-BPQIPLTHSA-N tert-butyl (2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-phenylmethoxypropyl]pyrrolidine-1-carboxylate Chemical compound O=C([C@H](C)[C@@H](OC)[C@H]1N(CCC1)C(=O)OC(C)(C)C)OCC1=CC=CC=C1 VZIUJIWPLDAAGJ-BPQIPLTHSA-N 0.000 description 1
- DLBZTAQYISLJFG-QGZVFWFLSA-N tert-butyl N-[(1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate Chemical compound C(C)(C)(C)OC(N[C@H](CC1=CC=CC=C1)C=1OC(=NN=1)C1=CC=CC=C1)=O DLBZTAQYISLJFG-QGZVFWFLSA-N 0.000 description 1
- UIPXTUUPKZTHLH-IKXXZMEWSA-N tert-butyl N-[(Z,2S)-1,5-diphenylpent-3-en-2-yl]carbamate Chemical compound C(C)(C)(C)OC(N[C@@H](CC1=CC=CC=C1)\C=C/CC1=CC=CC=C1)=O UIPXTUUPKZTHLH-IKXXZMEWSA-N 0.000 description 1
- DLBZTAQYISLJFG-KRWDZBQOSA-N tert-butyl n-[(1s)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C=1OC(=NN=1)C=1C=CC=CC=1)C1=CC=CC=C1 DLBZTAQYISLJFG-KRWDZBQOSA-N 0.000 description 1
- WNAHEVXTGAEKIY-CYBMUJFWSA-N tert-butyl n-[(2s)-1-phenylbut-3-en-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=C)CC1=CC=CC=C1 WNAHEVXTGAEKIY-CYBMUJFWSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940085503 testred Drugs 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229940111100 tice bcg Drugs 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 229950009158 tipifarnib Drugs 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940111528 trexall Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- WOPGHMKDMNSLIR-UHFFFAOYSA-M triphenyl(2-phenylethyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1CC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WOPGHMKDMNSLIR-UHFFFAOYSA-M 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- KIGCDEJCMKDBHU-NIQQUOCOSA-K ukrain Chemical compound [OH-].[OH-].[OH-].C([C@H](O)[C@@H]1C2=CC=C3OCOC3=C2C2)C3=CC=4OCOC=4C=C3[C@H]1[N+]2(C)CCNP(=S)(NCC[N+]1(C)[C@@H]2C3=CC=4OCOC=4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1)NCC[N+]1(C)[C@@H]2C3=CC(OCO4)=C4C=C3C[C@H](O)[C@@H]2C2=CC=C3OCOC3=C2C1 KIGCDEJCMKDBHU-NIQQUOCOSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 208000024722 urethra neoplasm Diseases 0.000 description 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950010938 valspodar Drugs 0.000 description 1
- 108010082372 valspodar Proteins 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 108700029852 vapreotide Proteins 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- 229940072018 zofran Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
Definitions
- the present patent application relates to novel derivatives of monomethylauristatin E and monomethylauristatin F, substituted with a carboxyalkyl group on the N terminus, methods of synthesis of these derivatives, use of these derivatives for treatment and/or prevention of diseases and use of these derivatives for production of pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases, such as the various forms of cancer, for example.
- Such treatments may be in the form of monotherapy or in combination with other drugs or other therapeutic measures.
- Cancer is the result of uncontrolled cell growth of a wide variety of tissues. In many cases, the new cells grow into existing tissue (invasive growth) or metastasize to remote organs. Cancer occurs in a wide variety of organs and the pathology often has a tissue-specific course.
- the term cancer is therefore a generic term that describes a large group of specific diseases of various organs, tissues and types of cells.
- Metastatic tumors can in some cases be removed by surgical and radiotherapeutic measures. Metastatic tumors can usually be treated only palliatively by chemotherapeutic agents. The goal here is to find the optimum combination of prolonging life and improving the quality of life.
- chemotherapeutic agents administered parenterally today are not distributed to the tumor tissue or tumor cells in a targeted manner but instead are nonspecifically distributed throughout the patient's body through systemic administration, i.e., at sites where exposure to the drug is often undesirable, such as in healthy cells, tissues and organs, for example. This may lead to adverse effects or even serious general toxic effects, which then often severely limit the therapeutically usable drug dosage range or necessitate complete cessation of the medication.
- Monoclonal antibodies are suitable for targeted addressing of tumor tissue and tumor cells.
- the importance of such antibodies for clinical treatment of cancer has grown enormously in recent years based on the efficacy of such agents as trastuzumab (Herceptin), rituximab (Rituxan), cetuximab (Erbitux) and bevacizumab (Avastin) which have been approved in the meantime for treatment of individual specific tumor conditions (see, for example, G. P. Adams and L. M. Weiner, Nat. Biotechnol. 23, 1147-1157 (2005)).
- binders from the field of small drug molecules may be used as binders to selectively bind to a specific “target” such as, for example, to a receptor (see, e.g., E. Ruoslahti et al., Science, 279, 377-380 (1998); D. Karkan et al., PLoS ONE 3 (6), e2469 (Jun. 25, 2008)).
- a specific “target” such as, for example, to a receptor
- Conjugates of a cytotoxic drug and an addressing ligand having a defined cleavage site between the ligand and the drug for release of the drug are also known.
- One such “intended breaking point” may consist of a peptide chain, for example, which can be cleaved selectively at a certain site by a specific enzyme at the site of action (see, for example, R. A. Firestone and L. A. Telan, US Patent Application US 2002/0147138).
- Auristatin E (AE) and monomethylauristatin E (MMAE) are synthetic analogs of the dolastatins, a special group of linear pseudopeptides, which were originally isolated from marine sources, and some of which have a very potent cytotoxic activity with respect to tumor cells (for an overview, see, for example, G. R. Pettit, Prog. Chem. Org. Nat. Prod. 70, 1-79 (1997); G. R. Pettit et al., Anti - Cancer Drug Design 10, 529-544 (1995); G. R. Pettit et al., Anti - Cancer Drug Design 13, 243-277 (1998)).
- MMAE has the disadvantage of a comparatively high systemic toxicity.
- this compound when used in the form of antibody-drug conjugates (immunoconjugates), this compound is not compatible with linking units (linkers) between antibody and active ingredient/drug, which do not have any enzymatically cleavable intended breaking points (S. O. Doronima et al., Bioconjugate Chem. 17, 114-124 (2006)).
- Monomethylauristatin F is an auristatin derivative with a C-terminal phenylalanine unit having only a moderate antiproliferative effect in comparison with MMAE. This can very likely be attributed to the free carboxyl group, which has a negative effect on the cell viability of this compound because of its polarity and charge.
- MMAF-OMe methyl ester of MMAF
- MMAF-OMe methyl ester of MMAF
- MMAF-OMe has been described as a prodrug derivative, which has a neutral charge and can pass through the cell membrane; it also has an increased in vitro cytotoxicity, which is greater by several orders of magnitude in comparison with MMAF with respect to various carcinoma cell lines. It may be assumed that this effect is caused by the MMAF itself, which is rapidly released by intracellular ester hydrolysis after the prodrug has been incorporated into the cells.
- auristatin derivatives such as MMAE and MMAF are also substrates for transporter proteins that are expressed by tumor cells, which can lead to the development of a resistance to these active ingredients.
- the object of the present invention was therefore to identify novel auristatin compounds and supply them for the treatment of cancer in particular, such that these auristatin compounds have a stronger cytotoxic activity in whole-cell assays in comparison with monomethylauristatin F (MMAF), which has only a moderate efficacy, and/or have less pronounced substrate properties for transporter proteins.
- MMAF monomethylauristatin F
- Such substances could also be especially suitable as toxophores for linking to proteins, such as antibodies in particular, or to low-molecular ligands to form (immuno-)conjugates having antiproliferative effects.
- MMAF Monomethylauristatin F
- MMAF analogs having a C-terminal amide-substituted phenylalanine unit are described in WO 01/18032 A2.
- MMAF analogs involving side chain modifications of phenylalanine are claimed in WO 02/088172 A2 and WO 2007/008603 A1, and WO 2007/008848 A2 describes those in which the carboxyl group of phenylalanine is modified.
- Additional auristatin conjugates linked via the N- or C-terminus are described in WO 2009/117531 A1 (see also S. O. Doronina et al., Bioconjugate Chem. 19, 1960-1963 (2008)).
- Compounds according to the invention include the compounds of formula (I) and their salts and solvates as well as the solvates of the salts, the compounds of the formulas given below that are covered by formula (I) and their salts and solvates as well as the solvates of the salts and the compounds covered by formula (I) and referred to below as exemplary embodiments as well as their salts and solvates as well as the solvates of the salts, as long as the compounds covered by formula (I) and listed below are not already the salts and solvates as well as the solvates of the salts.
- the compounds according to the invention may exist in different stereoisomeric forms depending on their structure, i.e., in the form of configurational isomers or optionally also as conformational isomers (enantiomers and/or diastereomers, including those in atropisomers).
- the present invention therefore includes the enantiomers and diastereomers and their respective mixtures.
- the stereoisomerically uniform components can be isolated in a known way from such mixtures of enantiomers and/or diastereomers. Chromatographic methods, in particular HPLC chromatography on a chiral or achiral phase, are preferably used for this purpose.
- the present invention also includes all the tautomeric forms.
- the preferred salts are the physiologically safe salts of the compounds according to the invention. This also includes salts that are not suitable for pharmaceutical applications per se but may be used for isolating or purifying the compounds according to the invention, for example.
- Physiologically safe salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid, naphthalene disulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- Physiologically safe salts of the compounds according to the invention also include the salts of conventional bases such as preferably and for example, alkali metal salts (e.g., sodium and potassium salts), alkaline earth salts (e.g., calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 carbon atoms, such as preferably and for example, ethylamine, diethylamine, triethylamine, N,N-diisopropylethyl amine, monoethanolamine, diethanolamine, triethanolamine, dimethylaminoethanol, diethylaminoethanol, procaine, dicyclohexylamine, dibenzyl-amine, N-methylpiperidine, N-methylmorpholine, arginine, lysine and 1,2-ethylene-diamine.
- alkali metal salts e.g., sodium and potassium salts
- alkaline earth salts e.g., calcium and magnesium salts
- solvates refer to forms of the compounds according to the invention which form a complex in a solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates in which molecules are coordinated with water. Hydrates are the preferred solvates within the scope of the present invention.
- the present invention also includes prodrugs of the compounds according to the invention.
- prodrugs here refers to compounds which may be biologically active or inactive themselves but are converted (e.g., metabolically or hydrolytically) to the compounds according to the invention during their dwell time in the body.
- (C 1 -C 4 )-Alkyl within the scope of the invention stands for a linear or branched alkyl radical with 1 to 4 carbon atoms. The following can be mentioned, preferably and for example: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
- (C 1 -C 12 )-Alkanediyl, (C 1 -C 8 )-alkanediyl and (C 1 -C 6 )-alkanediyl within the scope of the invention, stand for a linear ⁇ , ⁇ -divalent alkyl radical having 1 to 12, 1 to 8 or 1 to 6 carbon atoms.
- (C 1 -C 4 )-Alkanediyl within the scope of the invention, stands for a linear ⁇ , ⁇ -divalent alkyl radical having 1 to 4 carbon atoms.
- Preferred examples include: methylene, ethane-1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene) and butane-1,4-diyl (1,4-butylene).
- (C 2 -C 4 )-Alkenediyl within the scope of the invention, stands for a linear ⁇ , ⁇ -divalent alkenyl radical having 2 to 4 carbon atoms and a double bond.
- Preferred examples include: ethene-1,2-diyl, propene-1,3-diyl, but-1-ene-1,4-diyl and but-2-ene-1,4-diyl.
- the double bond here may be in a cis- or trans-configuration.
- (C 1 -C 12 )-Alkoxy within the scope of the invention, stands for a linear or branched alkoxy radical having 1 to 4 carbon atoms. Preferred examples include: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and tert-butoxy.
- (C 1 -C 4 )-Alkoxycarbonyl within the scope of the invention, stands for a linear or branched alkoxy radical having 1 to 4 carbon atoms, linked to the oxygen atom via a carbonyl group [—C( ⁇ O)—].
- Preferred examples include: methoxycarbonyl, ethoxy-carbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl and tert-butoxy-carbonyl.
- (C 3 -C 6 )-Cycloalkyl within the scope of the invention, stands for a monocyclic, saturated cycloalkyl group having 3 to 6 carbon atoms. Preferred examples include: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- a 5-membered heteroaryl in the definition of the ring Het stands for a divalent aromatic heterocycle (heteroaromatic) having a total of five ring atoms, containing up to three ring heteroatoms, which may be the same or different, from the series of N, O and/or S, and linked via two ring carbon atoms or optionally one ring nitrogen atom and one ring carbon atom.
- Examples include: furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2-thiazolyl, 1,3-thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl and 1,3,4-thiadiazolyl.
- a 5-membered heteroaryl having two or three heteroatoms which may be the same or different, from the series of N, O and/or S, such as in particular pyrazolyl, imidazolyl, 1,3-oxazolyl, 1,3-thiazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl and 1,3,4-oxadiazolyl.
- radicals that occur several times their meanings are independent of one another. If radicals are substituted in the compounds according to the invention, then the radicals may be substituted one or more times, unless otherwise specified. Substitution with one or two substituents that are the same or different is preferred. Substitution with one substituent is especially preferred.
- radicals given in detail in the respective combinations and/or preferred combinations of radicals are also replaced by definitions of any radicals in other combinations, regardless of the respective combinations indicated. Most especially preferred are combinations of two or more of the preferred ranges defined above.
- An additional subject matter of the present method is a method for preparing the compounds of formula (I) according to the invention, characterized in that a compound of formula (II)
- suitable inert solvents for the reaction of (II)+(III) ⁇ (IV) include ethers such as diethyl ether, diisopropyl ether, methyl-tert-butylmethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane, heptane, cyclohexane or petroleum fractions or dipolar aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N,N′-dimethylpropylene urea (DMPU), N-methylpyrrolidinone (NMP) or pyrrol
- Suitable bases for these alkylation reactions include in particular alkali hydroxides, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali carbonates or alkaline earth carbonates, such as lithium carbonate, sodium carbonate, potassium carbonate, calcium carbonate or cesium carbonate or the usual organic amines such as triethylamine, N-methylmorpholine, N-methylpiperidine, N,N-diisopropylethylamine, pyridine or 4-N,N-dimethylaminopyridine. Potassium or cesium carbonate is preferably used.
- alkali hydroxides such as lithium hydroxide, sodium hydroxide or potassium hydroxide
- alkali carbonates or alkaline earth carbonates such as lithium carbonate, sodium carbonate, potassium carbonate, calcium carbonate or cesium carbonate
- organic amines such as triethylamine, N-methylmorpholine, N-methylpiperidine, N,N-diisopropylethylamine,
- an alkylating catalyst such as lithium bromide or iodide, sodium or potassium iodide, tetra-n-butylammonium bromide or iodide or benzyltriethylammonium bromide, for example.
- the reaction (II)+(III) ⁇ (IV) is generally carried out in a temperature range from ⁇ 20° C. to +100° C., preferably at 0° C. to +50° C.
- the reaction may take place at normal, elevated or reduced pressure (e.g., from 0.5 bar to 5 bar). It is usually carried out under normal pressure.
- the reaction (II)+(V) ⁇ (VI) takes place in solvents that are inert under the reaction conditions and are typically used for reductive amination, optionally in the presence of an acid and/or a water-withdrawing agent as the catalyst.
- solvents include, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether or other solvents such as dichloromethane, 1,2-dichloroethane, N,N-dimethylformamide or even water Likewise, it is possible to use mixtures of these solvents.
- the preferred solvent for use here is a 1,4-dioxane/water mixture to which acetic acid or dilute hydrochloric acid is added as a catalyst
- Suitable reducing agents for this reaction include in particular complex borohydrides, such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride or tetra-n-butylammonium borohydride.
- complex borohydrides such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride or tetra-n-butylammonium borohydride.
- Sodium cyanoborohydride is preferred.
- the reaction (II)+(V) ⁇ (VI) is generally carried out in a temperature range from 0° C. to +120° C., preferably at +50° C. to +100° C.
- the reaction may take place at normal, elevated or reduced pressure (e.g., from 0.5 bar to 5 bar). It is usually carried out under normal pressure.
- the cleavage is preferably performed by using an acid.
- the cleavage may also take place by hydrogenolysis in the presence of a suitable palladium catalyst, such as palladium on activated carbon, for example.
- ester radical E 1 originating from compound (III) and/or (V) is selected here so that the conditions of its cleavage are compatible with the respective group T in compounds (IV) and (VI).
- the usual inorganic bases are suitable as the bases for ester hydrolysis. These include in particular alkali hydroxides or alkaline earth hydroxides such as lithium, sodium, potassium or barium hydroxide, or alkali carbonates or alkaline earth carbonates such as sodium, potassium or calcium carbonates. Lithium, sodium or potassium hydroxide is preferred.
- Suitable acids for the ester cleavage reaction include in general sulfuric acid, hydrochloric acid/hydrogen chloride, hydrobromic acid/hydrogen bromide, phosphoric acid, acetic acid, trifluoroacetic acid, toluenesulfonic acid, methanesulfonic acid or trifluoromethanesulfonic acid or mixtures thereof, optionally with the addition of water.
- Hydrochloric acid or trifluoroacetic acid are preferred in the case of a tert-butyl ester and hydrochloric acid is preferred in the case of a methyl ester.
- Suitable inert solvents for these reactions include water or the organic solvents typically used for ester cleavage. These preferably include low alcohols such as methanol, ethanol, n-propanol or isopropanol, ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane, or other solvents such as dichloromethane, acetone, methyl ethyl ketone, N,N-dimethylformamide or dimethyl sulfoxide. It is also possible to use mixtures of these solvents.
- low alcohols such as methanol, ethanol, n-propanol or isopropanol
- ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane
- other solvents such as dichloromethane, acetone, methyl ethyl ketone
- the ester cleavage generally takes place in a temperature range of ⁇ 20° C. to +100° C., preferably at 0° C. to +50° C.
- the compounds of formula (II) can be synthesized by the usual methods of peptide chemistry by coupling a compound of formula (VII)
- Inert solvents for these coupling reactions include, for example, ethers such as diethyl ether, diisopropyl ether, tert-butylmethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane, heptane, cyclohexane or petroleum fractions, halohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethylene or chlorobenzene or dipolar aprotic solvents such as acetone, methyl
- Suitable activation/condensation agents for these coupling reactions include, for example, carbodiimides such as N,N′-diethyl, N,N′-dipropyl, N,N′-diisopropyl, N,N′-dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), phosgene derivatives such as N,N′-carbonyldiimidazole (CDI) or isobutyl chloroformate, 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulfate or 2-tert-butyl-5-methylisoxazolium perchlorate, acylamino compounds, such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, ⁇ -chlorenamines such as
- the preferred activation/condensation agents for such coupling reactions include N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) in combination with 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), likewise in combination with N,N-diisopropylethylamine.
- EDC N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride
- HOBt 1-hydroxybenzotriazole
- HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
- the coupling reactions (VII)+(VIII) ⁇ (IX), (X)+(XI) ⁇ (XII) and (VII)+(XIII) ⁇ (XII) are usually performed in a temperature range from ⁇ 20° C. to +60° C., preferably at 0° C. to +40° C.
- the reactions may be performed under normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). It is customary to work under normal pressure.
- Such protective groups are introduced and removed according to the standard methods of peptide chemistry (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis , Wiley, New York, 1999; M. Bodanszky and A. Bodanszky, The Practice of Peptide Synthesis , Springer Verlag, Berlin, 1984). In the presence of several protected groups, they may optionally be released again simultaneously in either a one-pot reaction or in separate reaction steps.
- the preferred amino protective group is tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Z) or (9H-fluoren-9-ylmethoxy)carbonyl (Fmoc); tert-butyl or benzyl is preferably used as the protective group PG 2 for a hydroxyl or carboxyl function.
- a tert-butyl or tert-butoxycarbonyl group is usually split off by treating it with a strong acid such as hydrochloric acid, hydrobromic acid or trifluoroacetic acid in an inert solvent such as diethyl ether, 1,4-dioxane, dichloromethane or acetic acid.
- This reaction may optionally also be performed without adding an inert solvent.
- a protective group is preferably removed by hydrogenolysis in the presence of a suitable palladium catalyst, such as palladium on activated carbon, for example.
- a suitable palladium catalyst such as palladium on activated carbon, for example.
- the (9H-fluoren-9-ylmethoxy)carbonyl group is generally split off with the help of a secondary amine base, such as diethylamine or piperidine.
- the compounds of formula (VII) can be synthesized by a similar method, for example, by first coupling N-(benzyloxycarbonyl)-L-valine of formula (XIV)
- the ester group —C(O)O-E 3 is hydrolyzed in reaction step (XVIII) ⁇ (VII) in a process similar to that described above as part of the process sequences [A] and [B] for the ester radical E 1 .
- the alkyl group E 3 in compound (XV) is selected here so that the conditions of their cleavage are compatible with the respective protective group PG from compound (XVII).
- Boc and T have the meanings given above, and then splitting off the Boc protective group.
- the compounds according to the invention can expediently be separated into the corresponding enantiomers and/or diastereomers already at the stage of the compounds (II), (IV), (VI), (XI), (XII), (XIII) and (XX), which are then reacted further in isolated form according to the reaction steps described above.
- Such a separation of the stereoisomers can be performed according to the usual methods familiar to those skilled in the art. Chromatographic methods on chiral and/or achiral separation phases are preferably used. In the case of free carboxylic acids as the intermediates, separation via diastereomeric salts with the help of chiral bases may also be performed as an alternative.
- These compounds have valuable pharmacological properties and can be used for preventing and treating diseases humans and animals.
- the N-terminal carboxyalkyl group [HOOC-L- in formula (I)] present in the compounds according to the present invention does not have the mere function of a linker for the potential linkage to antibody proteins or other ligands, but instead is a constituent structural element for the surprisingly advantageous profile of properties of these compounds.
- These compounds according to the invention have a stronger cytotoxic activity in comparison with monomethylauristatin F (MMAF), for example, or have a reduced potential, while at the same time also being substrates for cellular transporter proteins.
- MMAF monomethylauristatin F
- the compounds according to the invention are therefore particularly suitable for treatment of hyperproliferative diseases in humans and mammals in general. These compounds can on the one hand inhibit, block, reduce or restrict cell proliferation and cell division while increasing apoptosis on the other hand.
- the hyperproliferative diseases for treatment of which the compounds according to the invention may be used include in particular the group of cancers and tumor diseases. These are understood to include in particular the following diseases within the scope of the present invention without being limited to these: breast cancer and breast tumors (ductile and lobular forms, also in situ), respiratory tract tumors (small cell and non-small-cell carcinomas, bronchial carcinoma), brain tumors (e.g., of the brain stem and the hypothalamus, astrocytoma, medulloblastoma, ependymoma and neuroectodermal and pineal tumors), tumors of the digestive tract (esophagus, stomach, gallbladder, small intestine, large intestine, rectum), liver tumors (including hepatocellular carcinoma, cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma), tumors of the head and neck area (larynx, hypopharynx, nasopharynx, or
- lymphomas include leukemias and myeloproliferative diseases, e.g., acute myeloid leukemia, acute lymphoblastic, chronic lymphocytic leukemia, chronic myelogenous leukemia and hairy cell leukemia as well as AIDS-related lymphomas, Hodgkin's lymphomas, non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, Burkitt's lymphomas and lymphomas of the central nervous system.
- lymphomas e.g., acute myeloid leukemia, acute lymphoblastic, chronic lymphocytic leukemia, chronic myelogenous leukemia and hairy cell leukemia as well as AIDS-related lymphomas, Hodgkin's lymphomas, non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, Burkitt's lymphomas and lymphomas of the central nervous system.
- Treatment of the types of cancer mentioned above by means of the compounds according to the invention includes treatment of such tumors as well as treatment of metastatic or circulating forms thereof.
- treatment or “to treat” are used in the conventional sense within the scope of this invention and refers to the care, treatment and consultation of a patient with the goal of combatting, reducing, diminishing or ameliorating a disease or health deviation and improving the quality of life, which is impaired by this disease, such as in a cancer, for example.
- An additional subject matter of the present invention thus relates to the use of the compounds according to the invention for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is the use of the compounds according to the invention for producing a pharmaceutical drug for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is the use of the compounds according to the invention in a method for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is a method for treatment and/or prevention of diseases, in particular the diseases cited above, using an effective amount of at least one of the compounds according to the invention.
- the compounds according to the invention may be used alone or, if necessary, in combination with one or more other pharmacologically active substances, as long as this combination does not lead to adverse effects and unacceptable side effects.
- Another subject matter of the present invention therefore relates to pharmaceutical drugs containing at least one of the compounds according to the invention and one or more additional active ingredients, in particular for treating and/or preventing the diseases listed above.
- the compounds according to the invention may be combined with known anti-hyperproliferative, cytostatic or cytotoxic substances, for example, for treatment of cancer.
- suitable combination drugs include the following:
- the compounds according to the present invention may be combined with antihyperproliferative agents, which may include the following, for example, although this list is not conclusive:
- the compounds according to the invention can also be combined with biological therapeutic agents such as antibodies (e.g., Avastin, Rituxan, Erbitux, Herceptin).
- the compounds according to the invention may also achieve positive effects in combination with treatments directed against angiogenesis, for example, with Avastin, axitinib, recentin, regorafenib, sorafenib or sunitinib.
- Combinations with inhibitors of the proteasome and of mTOR as well as combinations with antihormones and steroidal metabolic enzyme inhibitors are also especially suitable because of their favorable profile of side effects.
- the compounds according to the invention may also be used in combination with radiation therapy and/or a surgical intervention.
- Another subject matter of the present invention relates to pharmaceutical drugs containing at least one compound according to the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients as well as their use for the purposes indicated above.
- the compounds according to the invention may can systemically and/or topically. To this end, they are administered by a suitable route, for example, by an oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival or otic route or as an implant and/or a stent.
- a suitable route for example, by an oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival or otic route or as an implant and/or a stent.
- the compounds according to the invention may be administered in suitable dosage forms.
- the suitable dosage forms that function according to the state of the art and deliver the compounds according to the invention rapidly and/or in a modified form contain the compounds according to the invention in a crystalline and/or amorphized and/or dissolved form, e.g., tablets (coated or uncoated tablets, for example, with enteric coatings or insoluble coatings or those with a delayed release that control the release of the compound according to the invention), tablets or films/oblates that disintegrate rapidly in the mouth, films/lyophilisates, capsules (for example, hard or soft gelatin capsules), coated pills, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
- tablets coated or uncoated tablets, for example, with enteric coatings or insoluble coatings or those with a delayed release that control the release of the compound according to the invention
- tablets or films/oblates that disintegrate rapidly in the mouth films/lyophilisates
- capsules for example, hard or soft gelatin capsules
- coated pills
- Parenteral administration may be used to bypass a resorption step (e.g., intravenous, intra-arterial, intracardiac, intraspinal or intralumbar) or with the inclusion of resorption (e.g., intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal).
- a resorption step e.g., intravenous, intra-arterial, intracardiac, intraspinal or intralumbar
- Suitable dosage forms for parenteral administration include infusion and injection preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
- inhalation dosage forms including powder inhalers, nebulizers
- nose drops solutions or sprays
- tablets to be administered lingually, sublingually or buccally films, oblates or capsules, suppositories, ear or eye preparations, vaginal suppositories, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g., patches), milks, pastes, foams, dusting powders, implants or stents.
- Oral or parenteral administration is preferred, in particular oral and intravenous administration.
- the compounds according to the invention may be converted to the dosage forms indicated. This may be done in a known way by mixing with inert, non-toxic, pharmaceutically suitable excipients.
- excipients include, among others, vehicles (for example, microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example, sodium dodecyl sulfate, polyoxysorbitan oleate), binders (for example, polyvinyl pyrrolidone), synthetic and natural polymers (for example, albumin), stabilizers (e.g., antioxidants such as ascorbic acid), coloring agents (e.g., inorganic pigments such as iron oxides, for example) and taste and/or odor correcting substances).
- vehicles for example, microcrystalline cellulose, lactose, mannitol
- solvents e.g., liquid polyethylene glycols
- parenteral administration in general, it has proven advantageous to administer doses of approx. 0.001 to 1 mg/kg, preferably approx. 0.01 to 0.5 mg/kg body weight to achieve effective results.
- the dose is approx. 0.01 to 100 mg/kg, preferably approx. 0.01 to 20 mg/kg and most especially preferably 0.1 to 10 mg/kg body weight.
- Instrument Micromass Quattro Premier with Waters UPLC Acquity; column: Thermo Hypersil GOLD 1.9 ⁇ 50 mm ⁇ 1 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 90% A ⁇ 0.1 min 90% A ⁇ 1.5 min 10% A ⁇ 2.2 min 10% A; flow rate: 0.33 mL/min; oven: 50° C.; UV detection: 210 nm.
- Instrument type MS Micromass ZQ
- instrument type HPLC HP 1100 series
- UV DAD column: Phenomenex Gemini 3 ⁇ 30 mm ⁇ 3.00 mm
- eluent A 1 liter water+0.5 mL 50% formic acid
- eluent B 1 liter acetonitrile+0.5 mL 50% formic acid
- flow rate 0.0 min 1 mL/min)->2.5 min/3.0 min/4.5 min 2 mL/min
- UV detection 210 nm.
- Instrument type Waters ZQ; instrument type HPLC: Agilent 1100 series; UV DAD; column: Thermo Hypersil GOLD 3 ⁇ 20 mm ⁇ 4 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 100% A ⁇ 3.0 min 10% A ⁇ 4.0 min 10% A ⁇ 4.1 min 100% A (flow rate: 2.5 mL/min); oven: 55° C.; flow rate: 2 mL/min; UV detection: 210 nm.
- Instrument type MS Waters ZQ; instrument type HPLC: Agilent 1100 series; UV DAD; column: Thermo Hypersil GOLD 3 ⁇ 20 mm ⁇ 4 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 100% A ⁇ 2.0 min 60% A ⁇ 2.3 min 40% A ⁇ 3.0 min 20% A ⁇ 4.0 min 10% A ⁇ 4.2 min 100% A (flow rate: 2.5 mL/min); oven: 55° C.; flow rate: 2 mL/min; UV detection: 210 nm.
- Instrument Micromass GCT, GC 6890; column: Restek RTX-35, 15 m ⁇ 200 ⁇ m ⁇ 0.33 ⁇ m; constant flow rate of helium: 0.88 mL/min; oven: 70° C.; inlet: 250° C.; gradient: 70° C., 30° C./min ⁇ 310° C. (3 min hold).
- the title compound can be synthesized by various methods according to procedures described in the literature; see, e.g., Pettit et al., Synthesis 1996, 719; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913; Koga et al., Tetrahydron Lett. 1991, 32, 2395; Vidal et al., Tetrahedron 2004, 60, 9715; Poncet et al., Tetrahedron 1994, 50, 5345. It was synthesized here according to the procedure by Shioiri et al. ( Tetrahedron Lett. 1991, 32, 931).
- the title compound can be synthesized by various methods described in the literature; see, e.g., Pettit et al., J. Org. Chem. 1994, 59, 1796; Koga et al., Tetrahedron Lett. 1991, 32, 2395; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913. It was synthesized here according to the procedure by Koga et al. ( Tetrahedron Lett. 1991, 32, 2395).
- the batch was then poured into a mixture of 50% saturated aqueous ammonium chloride solution and ethyl acetate.
- the organic phase was separated, washed in succession with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated. The residue was used directly in the next step without further purification.
- N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-tert-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 3) was dissolved in 5 mL dichloromethane, mixed with 5 mL trifluoroacetic acid and stirred over night at RT. Then the mixture was concentrated in vacuo, and the remaining residue was purified by preparative HPLC, yielding 430 mg (72% of the theoretical) of the title compound as a colorless foam.
- N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide (intermediate 4) was dissolved in 10 mL DMF and mixed with 0.5 mL piperidine. After stirring for 10 min at RT, the batch was concentrated in vacuo and the residue was stirred with diethyl ether. The insoluble ingredients were filtered out and washed several times with diethyl ether.
- the filter residue was dissolved in 5 mL dioxane/water (1:1) and the solution was adjusted to pH 11 with 1N sodium hydroxide solution. While treating with ultrasound, a total of 349 mg (1.6 mmol) di-tert-butyl dicarbonate was added in several portions, while the pH of the solution was kept at 11. After the end of the reaction, the dioxane was evaporated and the pH of the aqueous solution was adjusted to 2-3 with citric acid. Extraction was performed twice with 50 mL ethyl acetate each time. The organic phases were combined, dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in diethyl ether and the product was precipitated with pentane. The solvent was separated by decanting. The residue was digested again with pentane and finally dried in a high vacuum, yielding 31 mg (93% of the theoretical) of the title compound.
- (2R,3R)-3-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methyl-propanoic acid was released from 1.82 g (3.88 mmol) of the dicyclohexylamine salt (starting compound 1) by dissolving it in 150 mL ethyl acetate and extracting with 100 mL 0.5% aqueous sulfuric acid. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was dissolved in 10 mL dioxane and 10 mL water, mixed with 1517 mg (4.66 mmol) cesium carbonate and treated for 5 min in an ultrasonic bath.
- the total amount of the intermediate obtained was dissolved in 25 mL of a mixture of methanol and dichloromethane (20:1) and the benzyl ester group was removed by hydrogenation under normal pressure with 10% palladium on activated carbon as the catalyst. After stirring for 30 min at RT, the catalyst was filtered out and the filtrate was concentrated in vacuo, yielding 803 mg (91% of the theoretical) of the title compound as a white solid.
- the crude intermediate obtained above was dissolved in a solution of 2 mL 30% hydrogen peroxide and 5 mL formic acid and stirred for 12 h at RT. Then the reaction mixture was poured into saturated aqueous sodium sulfate solution and extracted three times with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated in vacuo. The resulting raw product was purified by preparative HPLC, thus yielding 343 mg (61% of the theoretical) of the title compound.
- the E/Z diastereomer mixture obtained above was dissolved in 2 mL ethanol and 0.2 mL N,N-diisopropylethylamine and separated over HPLC on a chiral phase [column: Daicel Chiralpak AD-H, 5 ⁇ m, 250 mm ⁇ 20 mm; eluent: hexane/(ethanol+0.2% diethylamine) 50:50 v/v; UV detection: 220 nm; temperature: 30° C.]. The corresponding fractions were concentrated on a rotary evaporator and the residue was dried in vacuo, yielding 10 mg of the title compound as a pure Z isomer.
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-3- ⁇ [(2S,3Z)-1,4-diphenylbut-3-en-2-yl]amino ⁇ -1-methoxy-2-methyl-3-oxopropyl]-pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-3- ⁇ [(2S,3E)-1,4-diphenylbut-3-en-2-yl]amino ⁇ -1-methoxy-2-methyl-3-oxopropyl]-pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-3- ⁇ [(2S)-1-benzylsulfonyl)-3-phenylpropan-2-yl]amino ⁇ -1-methoxy-2-methyl-3-oxo-propyl]pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl ⁇ -3-methoxy
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1- ⁇ (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3- ⁇ [(1S)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]amino ⁇ propyl]pyrrolidin-1-yl ⁇ -5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1- ⁇ (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3- ⁇ [(1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]amino ⁇ propyl]pyrrolidin-1-yl ⁇ -5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl
- N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1- ⁇ (2S)-2-[(1R,2R)-1-methoxy-3- ⁇ [(2S,3E)-4-[4-(methoxycarbonyl)phenyl]-1-phenylbut-3-en-2-yl ⁇ amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 ⁇ mol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1
- the title compound was synthesized by analogy with the synthesis process of Example 1 by reacting 100 mg (119 ⁇ mol) N-methyl-L-valyl-N-[(3R,4S,5S)-1- ⁇ (2S)-2-[(1R,2R)-3- ⁇ [2-(1H-indol-3-yl)ethyl]amino ⁇ -1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl ⁇ -3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 24) with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride.
- reaction mixture was stirred over night at RT, then acidified by adding 1N hydrochloric acid and extracted twice with 10 mL each time. The combined organic phases were dried over magnesium sulfate and concentrated, yielding 18.3 mg (84% purity, 46% of the theoretical) of the title compound.
- the biological activity of the compounds according to the invention can be demonstrated by in vitro and in vivo investigations, such as those with which those skilled in the art are familiar.
- the pharmacological and pharmacokinetic properties of the compounds can according to the invention be determined with the help of the assays described below.
- a defined cell count of the human colon carcinoma cell line HT29 wt (wild type) was sown in a 96-well microtiter plate in whole medium (10% FCS-RPMI) (2500 cells/well) and incubated overnight at 37° C./5% CO 2 . After 18 hours, the inoculation medium was replaced by fresh medium with 10% FCS. The treatment started with addition of the respective test substance. Of the substances to be investigated, dose-effect curves were determined in a concentration range of 10 ⁇ 5 M to 10 ⁇ 14 M (1:10 dilution series). Incubation times of 48 h to 96 h were selected. Proliferation was detected with the help of the MTT assay (ATCC, Manassas, Va., USA, catalog no.
- the MTT reagent was incubated with the cells for 4 h before lysis of the cells was performed overnight by adding the detergent.
- the dye that was formed was detected at 570 nm.
- the proliferation with otherwise identically treated cells but not with the test substance was defined as the 100% value.
- the data obtained from this test represents triple determinations, and at least two independent experiments were performed.
- MMAF monomethylauristatin F
- Cancer cells are degenerate or neoplastic cells, which often lead to development of a tumor through increased cell division.
- Microtubules form the spindle fibers of the spindle apparatus and are an essential component of the cell cycle. Regulated buildup and breakdown of microtubule permit an accurate distribution of chromosomes to the daughter cells and represent a continuous dynamic process. A disturbance in these dynamics leads to faulty cell division and ultimately to cell death.
- the increased cell division of cancer cells makes them especially susceptible to spindle fiber toxins, which are a fixed component of chemotherapy.
- GTP is added to unpolymerized tubulin, so the polymerization can take place spontaneously.
- the assay is based on the binding of the fluorophore 4′,6-diamidino-2-phenylindole (DAPI) to tubulin. Free and bound DAPI can be differentiated on the basis of different emission spectra. DAPI has a much higher affinity for polymerized tubulin in comparison with unpolymerized tubulin, so tubulin polymerization can be tracked on the basis of the increase in the fluorescence of bound DAPI fluorophores.
- DAPI fluorophore 4′,6-diamidino-2-phenylindole
- test substances dissolved in DMSO were diluted in water from their initial concentration of 10 mM to 1 ⁇ M.
- buffer controls polymerization-increasing paclitaxel and polymerization-inhibiting vinblastine were also included as assay controls.
- 96-well plates with a half bottom area were used, tracking the kinetics of the tubulin polymerization for one hour at 37° C. in a fluorimeter.
- the excitation wavelength was 355 nm, and the emission was tracked at 460 nm.
- the change in fluorescence per minute ( ⁇ F/min) was calculated, representing the rate of polymerization of the microtubules.
- the potency of the test substances was quantified on the basis of the respective reduction in the rate of polymerization.
- Instrument Agilent 1200 with DAD, binary pump, autosampler, column oven and thermostat; column: Kromasil 100 C18, 250 mm ⁇ 4 mm, 5 ⁇ m; column temperature: 45° C.; eluent A: 5 mL perchloric acid/L water; eluent B: acetonitrile; gradient: 0-8 min 98% A, 2% B: 8-15 min 56% A, 44% B; 15-20 min 10% A, 90% B; 20-21 min 10% A, 90% B; 21-23 min 98% A, 2% B; 23-25 min 98% A, 2% B; flow rate: 2 mL/min; UV detection: 220 nm.
- test substance was incubated in rat plasma and/or human plasma at 37° C. for a period of 5 h while stirring lightly. At various points in time (0, 2, 5, 10, 20, 30, 60, 120, 180 and 300 minutes), a 100 ⁇ L aliquot was taken. After adding an internal standard (10 ⁇ L), the proteins were precipitated by adding 200 ⁇ L and the mixture was centrifuged for 5 minutes in an Eppendorf centrifuge. After adding 150 ⁇ L ammonium acetate buffer, pH 3, to 150 ⁇ L of the supernatant, the unchanged test substance content was analyzed by LC/MSMS.
- the cell permeability of a substance can be analyzed by in vitro testing in a flux assay using Caco-2 cells [M. D. Troutman and D. R. Thakker, Pharm. Res. 20 (8), 1210-1224 (2003)]. To do so, the cells were cultured for 15-16 days on 24-hole filter plates. To determine the permeation, the respective test substance was applied to the cells either apically (A) or basally (B) in a HEPES buffer and incubated for 2 h. After 0 h and after 2 h, samples were taken from the cis- and trans-compartments. The samples were separated by HPLC (Agilent 1200, Böblingen, Germany) using reverse phase columns.
- the HPLC system was coupled via a turbo ion spray interface to an API 4000 triple quadrupole mass spectrometer (Applied Biosystems Applera, Darmstadt, Germany).
- the permeability was evaluated on the basis of a P app value, which was calculated using the equation published by Schwab et al. [D. Schwab et al., J. Med. Chem. 46, 1717-1725 (2003)].
- a substance was classified as being actively transported if the ratio of P app (B ⁇ A) to P app (A ⁇ B) was >2 or ⁇ 0.5.
- Table 2 below shows permeability data for representative exemplary embodiments from this assay:
- MMAE monomethylauristatin E
- MMAF monomethylauristatin F
- P-glycoprotein (P-gp) or BCRP could thus have an improved profile of effect.
- the substrate properties of a substance for P-gp were determined by means of a flux assay using LLC-PK1 cells which overexpress P-gp (L-MDR1 cells) [A. H. Schinkel et al., J. Clin. Invest. 96, 1698-1705 (1995)]. To do so, the LLC-PK1 cells or L-MDR1 cells were cultured for 3-4 days on 96-well filter plates. To determine the permeation, the respective test substance, either alone or in the presence of an inhibitor (e.g., ivermectin or verapamil) in a HEPES buffer was applied to the cells either apically (A) or basally (B) and incubated for 2 h.
- an inhibitor e.g., ivermectin or verapamil
- the efflux ratios in L-MDR1 and LLC-PK1 cells or the efflux ratio in the presence or absence of an initiator can be compared with one another as additional criteria for evaluating the P-gp substrate properties. If these values differ by more than a factor of 2, then the respective substance is a P-gp substrate.
- the compounds according to the invention may be converted to pharmaceutical preparations by the following method:
- the mixture of the compound according to the invention, lactose and starch is granulated with a 5% solution (w/w) of the PVP in water.
- the granules are mixed with the magnesium stearate for five minutes after drying.
- This mixture is pressed with a conventional tablet press (see above for the format of the tablet).
- a pressing force of 15 kN was used as the guideline value for pressing the tablets.
- 10 mL oral suspension corresponds to a single dose of 100 mg of the compound according to the invention.
- 500 mg of the compound according to the invention, 2.5 g polysorbate and 97 g polyethylene glycol 400.20 g of the oral solution corresponds to a single dose of 100 mg of the compound according to the invention.
- the compound according to the invention is suspended in the mixture of polyethylene glycol and polysorbate while stirring. The stirring process is continued until the compound according to the invention is completely dissolved.
- the compound according to the invention is dissolved in a concentration below the saturation solubility in a physiologically tolerable solvent (e.g., isotonic saline solution, glucose solution 5% and/or PEG 400 solution 30%).
- a physiologically tolerable solvent e.g., isotonic saline solution, glucose solution 5% and/or PEG 400 solution 30%.
- the solution is sterile filtered and bottled in sterile and pyrogen-free injection vials.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- The present patent application relates to novel derivatives of monomethylauristatin E and monomethylauristatin F, substituted with a carboxyalkyl group on the N terminus, methods of synthesis of these derivatives, use of these derivatives for treatment and/or prevention of diseases and use of these derivatives for production of pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases, such as the various forms of cancer, for example. Such treatments may be in the form of monotherapy or in combination with other drugs or other therapeutic measures.
- Cancer is the result of uncontrolled cell growth of a wide variety of tissues. In many cases, the new cells grow into existing tissue (invasive growth) or metastasize to remote organs. Cancer occurs in a wide variety of organs and the pathology often has a tissue-specific course. The term cancer is therefore a generic term that describes a large group of specific diseases of various organs, tissues and types of cells.
- Early-stage tumors can in some cases be removed by surgical and radiotherapeutic measures. Metastatic tumors can usually be treated only palliatively by chemotherapeutic agents. The goal here is to find the optimum combination of prolonging life and improving the quality of life.
- Most chemotherapeutic agents administered parenterally today are not distributed to the tumor tissue or tumor cells in a targeted manner but instead are nonspecifically distributed throughout the patient's body through systemic administration, i.e., at sites where exposure to the drug is often undesirable, such as in healthy cells, tissues and organs, for example. This may lead to adverse effects or even serious general toxic effects, which then often severely limit the therapeutically usable drug dosage range or necessitate complete cessation of the medication.
- The improved and selective availability of these chemotherapeutic agents in the tumor cell or the immediate surrounding tissue and the associated increase in effect, on the one hand, and minimization of toxic side effects, on the other hand, have therefore for many years been the focus of work in developing new chemotherapeutic drugs. There have been numerous attempts so far to develop efficient methods for introducing drugs into the target cell. However, it is still a difficult task to optimize the association between the drug and the intracellular target and to minimize the intercellular distribution of the drug, e.g., to neighboring cells.
- Monoclonal antibodies, for example, are suitable for targeted addressing of tumor tissue and tumor cells. The importance of such antibodies for clinical treatment of cancer has grown enormously in recent years based on the efficacy of such agents as trastuzumab (Herceptin), rituximab (Rituxan), cetuximab (Erbitux) and bevacizumab (Avastin) which have been approved in the meantime for treatment of individual specific tumor conditions (see, for example, G. P. Adams and L. M. Weiner, Nat. Biotechnol. 23, 1147-1157 (2005)). As a result, there has been a significant increase in interest in so-called immunoconjugates, in which an internalizing antibody directed against a tumor-associated antigen is bound covalently to a cytotoxic agent by a linking unit (“linker”). After introducing the conjugate into the tumor cell and then it splitting it off, the cytotoxic agent is released inside the tumor cell, where it can manifest its effect directly and selectively. In this way, the damage to normal tissue can be kept within significantly narrower limits in comparison with conventional chemotherapy for cancer (see, for example, J. M. Lambert, Curr. Opin. Pharmacol. 5, 543-549 (2005); A. M. Wu and P. D. Senter, Nat. Biotechnol. 23, 1137-1146 (2005); P. D. Senter, Curr. Opin. Chem. Biol. 13, 235-244 (2009); L. Ducry and B. Stump, Bioconjugate Chem. 21, 5-13 (2010)).
- Instead of antibodies, binders from the field of small drug molecules may be used as binders to selectively bind to a specific “target” such as, for example, to a receptor (see, e.g., E. Ruoslahti et al., Science, 279, 377-380 (1998); D. Karkan et al., PLoS ONE 3 (6), e2469 (Jun. 25, 2008)). Conjugates of a cytotoxic drug and an addressing ligand having a defined cleavage site between the ligand and the drug for release of the drug are also known. One such “intended breaking point” may consist of a peptide chain, for example, which can be cleaved selectively at a certain site by a specific enzyme at the site of action (see, for example, R. A. Firestone and L. A. Telan, US Patent Application US 2002/0147138).
- Auristatin E (AE) and monomethylauristatin E (MMAE) are synthetic analogs of the dolastatins, a special group of linear pseudopeptides, which were originally isolated from marine sources, and some of which have a very potent cytotoxic activity with respect to tumor cells (for an overview, see, for example, G. R. Pettit, Prog. Chem. Org. Nat. Prod. 70, 1-79 (1997); G. R. Pettit et al., Anti-Cancer Drug Design 10, 529-544 (1995); G. R. Pettit et al., Anti-Cancer Drug Design 13, 243-277 (1998)).
- However, MMAE has the disadvantage of a comparatively high systemic toxicity. Furthermore, when used in the form of antibody-drug conjugates (immunoconjugates), this compound is not compatible with linking units (linkers) between antibody and active ingredient/drug, which do not have any enzymatically cleavable intended breaking points (S. O. Doronima et al., Bioconjugate Chem. 17, 114-124 (2006)).
- Monomethylauristatin F (MMAF) is an auristatin derivative with a C-terminal phenylalanine unit having only a moderate antiproliferative effect in comparison with MMAE. This can very likely be attributed to the free carboxyl group, which has a negative effect on the cell viability of this compound because of its polarity and charge. In this context, the methyl ester of MMAF (MMAF-OMe) has been described as a prodrug derivative, which has a neutral charge and can pass through the cell membrane; it also has an increased in vitro cytotoxicity, which is greater by several orders of magnitude in comparison with MMAF with respect to various carcinoma cell lines (S. O. Doronina et al., Bioconjugate Chem. 17, 114-124 (2006)). It may be assumed that this effect is caused by the MMAF itself, which is rapidly released by intracellular ester hydrolysis after the prodrug has been incorporated into the cells.
- However, drug compounds based on simple ester derivatives are generally at risk of chemical instability due to a nonspecific ester hydrolysis, which is independent of the intended site of action, for example, due to esterases present in blood plasma. This can greatly restrict the usability of such compounds in treatment. In addition, auristatin derivatives such as MMAE and MMAF are also substrates for transporter proteins that are expressed by tumor cells, which can lead to the development of a resistance to these active ingredients.
- The object of the present invention was therefore to identify novel auristatin compounds and supply them for the treatment of cancer in particular, such that these auristatin compounds have a stronger cytotoxic activity in whole-cell assays in comparison with monomethylauristatin F (MMAF), which has only a moderate efficacy, and/or have less pronounced substrate properties for transporter proteins. Such substances could also be especially suitable as toxophores for linking to proteins, such as antibodies in particular, or to low-molecular ligands to form (immuno-)conjugates having antiproliferative effects.
- Monomethylauristatin F (MMAF) as well as various ester and amide derivatives thereof were disclosed in WO 2005/081711 A2. Additional auristatin analogs having a C-terminal amide-substituted phenylalanine unit are described in WO 01/18032 A2. MMAF analogs involving side chain modifications of phenylalanine are claimed in WO 02/088172 A2 and WO 2007/008603 A1, and WO 2007/008848 A2 describes those in which the carboxyl group of phenylalanine is modified. Additional auristatin conjugates linked via the N- or C-terminus are described in WO 2009/117531 A1 (see also S. O. Doronina et al., Bioconjugate Chem. 19, 1960-1963 (2008)).
- The subject matter of the present invention is compounds of general formula (I):
- in which
- L stands for linear (C1-C12)-alkanediyl, which may be substituted with methyl up to four times and in which (a) two carbon atoms in 1,2-, 1,3- or 1,4-relation to one another may be bridged by including the carbon atoms optionally between them to form a (C3-C6)-cycloalkyl ring or a phenyl ring, or (b) up to three CH2 groups not vicinal to one another may be replaced by —O—,
and - T stands for a group of the formula
- wherein
-
- * denotes the linkage site to the nitrogen atom,
- R1 stands for phenyl or 1H-indol-3-yl,
- and
- R2 stands for hydrogen or a group of the formula
-
- wherein
- ** denotes the respective linkage site to the radical of the respective group T,
- A stands for linear (C1-C4)-alkanediyl or linear (C2-C4)-alkenediyl,
- R3 stands for phenyl that may be substituted with (C1-C4)-alkoxycarbonyl or carboxyl,
- n stands for the number 0, 1 or 2,
- R4 stands for phenyl, benzyl or 2-phenylethyl which may be substituted with (C1-C4)-alkoxycarbonyl or carboxyl in the phenyl group
- Het stands for a divalent 5-membered heteroaryl ring with up to three ring heteroatoms from the series N, O and/or S,
- and
- R5 stands for (C3-C6)-cycloalkyl, phenyl or (C1-C4)-alkyl, which may be substituted with phenyl,
- wherein the aforementioned phenyl groups may in turn be substituted with (C1-C4)-alkoxycarbonyl or carboxyl,
- as well as their salts and solvates and the solvates of the salts.
- Compounds according to the invention include the compounds of formula (I) and their salts and solvates as well as the solvates of the salts, the compounds of the formulas given below that are covered by formula (I) and their salts and solvates as well as the solvates of the salts and the compounds covered by formula (I) and referred to below as exemplary embodiments as well as their salts and solvates as well as the solvates of the salts, as long as the compounds covered by formula (I) and listed below are not already the salts and solvates as well as the solvates of the salts.
- The compounds according to the invention may exist in different stereoisomeric forms depending on their structure, i.e., in the form of configurational isomers or optionally also as conformational isomers (enantiomers and/or diastereomers, including those in atropisomers). The present invention therefore includes the enantiomers and diastereomers and their respective mixtures. The stereoisomerically uniform components can be isolated in a known way from such mixtures of enantiomers and/or diastereomers. Chromatographic methods, in particular HPLC chromatography on a chiral or achiral phase, are preferably used for this purpose.
- If the compounds according to the invention can occur in tautomeric forms, then the present invention also includes all the tautomeric forms.
- Within the scope of the present invention, the preferred salts are the physiologically safe salts of the compounds according to the invention. This also includes salts that are not suitable for pharmaceutical applications per se but may be used for isolating or purifying the compounds according to the invention, for example.
- Physiologically safe salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid, naphthalene disulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- Physiologically safe salts of the compounds according to the invention also include the salts of conventional bases such as preferably and for example, alkali metal salts (e.g., sodium and potassium salts), alkaline earth salts (e.g., calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 carbon atoms, such as preferably and for example, ethylamine, diethylamine, triethylamine, N,N-diisopropylethyl amine, monoethanolamine, diethanolamine, triethanolamine, dimethylaminoethanol, diethylaminoethanol, procaine, dicyclohexylamine, dibenzyl-amine, N-methylpiperidine, N-methylmorpholine, arginine, lysine and 1,2-ethylene-diamine.
- Within the scope of the invention, solvates refer to forms of the compounds according to the invention which form a complex in a solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates in which molecules are coordinated with water. Hydrates are the preferred solvates within the scope of the present invention.
- Furthermore, the present invention also includes prodrugs of the compounds according to the invention. The term “prodrugs” here refers to compounds which may be biologically active or inactive themselves but are converted (e.g., metabolically or hydrolytically) to the compounds according to the invention during their dwell time in the body.
- Within the scope of the present invention, the substituents have the following meanings, unless otherwise specified:
- (C1-C4)-Alkyl within the scope of the invention stands for a linear or branched alkyl radical with 1 to 4 carbon atoms. The following can be mentioned, preferably and for example: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
- (C1-C12)-Alkanediyl, (C1-C8)-alkanediyl and (C1-C6)-alkanediyl, within the scope of the invention, stand for a linear α,ω-divalent alkyl radical having 1 to 12, 1 to 8 or 1 to 6 carbon atoms. A linear alkanediyl group having 1 to 8, especially preferably 1 to 6 carbon atoms is preferred. The following can be mentioned preferably and for example: methylene, ethane-1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene), butane-1,4-diyl (1,4-butylene), pentane-1,5-diyl (1,5-pentylene), hexane-1,6-diyl (1,6-hexylene), heptane-1,7-diyl (1,7-hexylene), octane-1,8-diyl (1,8-octylene), nonane-1,9-diyl (1,9-nonylene), decane-1,10-diyl (1,10-decylene), undecane-1,11-diyl (1,11-undecylene) and dodecane-1,12-diyl (1,12-dodecylene).
- (C1-C4)-Alkanediyl, within the scope of the invention, stands for a linear α,ω-divalent alkyl radical having 1 to 4 carbon atoms. Preferred examples include: methylene, ethane-1,2-diyl (1,2-ethylene), propane-1,3-diyl (1,3-propylene) and butane-1,4-diyl (1,4-butylene).
- (C2-C4)-Alkenediyl, within the scope of the invention, stands for a linear α,ω-divalent alkenyl radical having 2 to 4 carbon atoms and a double bond. Preferred examples include: ethene-1,2-diyl, propene-1,3-diyl, but-1-ene-1,4-diyl and but-2-ene-1,4-diyl. The double bond here may be in a cis- or trans-configuration.
- (C1-C12)-Alkoxy, within the scope of the invention, stands for a linear or branched alkoxy radical having 1 to 4 carbon atoms. Preferred examples include: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and tert-butoxy.
- (C1-C4)-Alkoxycarbonyl, within the scope of the invention, stands for a linear or branched alkoxy radical having 1 to 4 carbon atoms, linked to the oxygen atom via a carbonyl group [—C(═O)—]. Preferred examples include: methoxycarbonyl, ethoxy-carbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl and tert-butoxy-carbonyl.
- (C3-C6)-Cycloalkyl, within the scope of the invention, stands for a monocyclic, saturated cycloalkyl group having 3 to 6 carbon atoms. Preferred examples include: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- A 5-membered heteroaryl in the definition of the ring Het, stands for a divalent aromatic heterocycle (heteroaromatic) having a total of five ring atoms, containing up to three ring heteroatoms, which may be the same or different, from the series of N, O and/or S, and linked via two ring carbon atoms or optionally one ring nitrogen atom and one ring carbon atom. Examples include: furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, 1,2-oxazolyl, 1,3-oxazolyl, 1,2-thiazolyl, 1,3-thiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl and 1,3,4-thiadiazolyl. A 5-membered heteroaryl having two or three heteroatoms, which may be the same or different, from the series of N, O and/or S, such as in particular pyrazolyl, imidazolyl, 1,3-oxazolyl, 1,3-thiazolyl, 1,2,4-triazolyl, 1,2,4-oxadiazolyl and 1,3,4-oxadiazolyl.
- Within the scope of the present invention, it is true that for all radicals that occur several times, their meanings are independent of one another. If radicals are substituted in the compounds according to the invention, then the radicals may be substituted one or more times, unless otherwise specified. Substitution with one or two substituents that are the same or different is preferred. Substitution with one substituent is especially preferred.
- Preferred within the scope of the present invention are compounds of formula (I) in which:
- L stands for linear (C1-C8)-alkanediyl, in which (a) two carbon atoms in 1,3- or 1,4-relation to one another may be bridged by including one or two of the carbon atoms between them to form a phenyl ring, or (b) up to two CH2 groups not vicinal to one another may be replaced by —O—,
and - T stands for a group of the formula
- wherein
-
- * denotes the linkage site to the nitrogen atom,
- R1 denotes phenyl or 1H-indol-3-yl,
- and
- R2 denotes hydrogen or a group of the formula
-
- wherein
- ** denotes the linkage site to the radical of the respective group T,
- A denotes ethene-1,2-diyl or propene-1,3-diyl,
- R3 stands for phenyl, which may be substituted with (C1-C4)-alkoxycarbonyl or carboxyl,
- Het is a divalent 5-membered heteroaryl ring selected from the series of pyrazolyl, imidazolyl, 1,3-oxazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl and 1,3,4-oxadiazolyl,
- and
- R5 denotes a phenyl, which may be substituted with (C1-C4)-alkoxycarbonyl or carboxyl,
- as well as their salts and solvates and the solvates of the salts.
- Especially preferred within the scope of the present invention are compounds of formula (I) in which:
- L stands for linear (C1-C6)-alkanediyl,
and - T stands for a group of the formula
- wherein
-
- * denotes the linkage site to the nitrogen atom,
- and
- R2 denotes hydrogen or a group of the formula
-
- wherein
- ** denotes the linkage site to the radical of the respective group T,
- A denotes ethene-1,2-diyl,
- R3 denotes phenyl, which may be substituted with methoxycarbonyl or carboxyl,
- Het is 1,3,4-oxadiazol-2,5-yl,
- and
- R5 is a phenyl, which may be substituted with methoxycarbonyl or carboxyl,
- as well as their salts and solvates and the solvates of the salts.
- Especially important within the scope of the present invention are compounds of formula (I), in which:
- L stands for propane-1,3-diyl,
as well as their salts and solvates and the solvates of the salts. - Especially important within the scope of the present invention are compounds of formula (I), in which:
- T stands for a group of the formula
-
- in which
- * denotes the linkage site to the nitrogen atom,
- and
- R2A has the meanings of R2 defined above, but does not stand for hydrogen,
as well as their salts and solvates and the solvates of the salts.
- The definitions of the radicals given in detail in the respective combinations and/or preferred combinations of radicals are also replaced by definitions of any radicals in other combinations, regardless of the respective combinations indicated. Most especially preferred are combinations of two or more of the preferred ranges defined above.
- An additional subject matter of the present method is a method for preparing the compounds of formula (I) according to the invention, characterized in that a compound of formula (II)
- in which T has the meanings given above,
is reacted in an inert solvent, either - [A] by base-induced alkylation with a compound of formula (III)
-
- in which L has the meaning given above,
- E1 stands for hydrogen, (C1-C4)-alkyl or benzyl,
- and
- X stands for a leaving group, such as chloride, bromide, iodide, mesylate, triflate or tosylate,
- to form a compound of formula (IV)
-
- in which E1, L and T have the meanings given above,
- and then in the case when E1 stands for (C1-C4)-alkyl or benzyl, this ester radical is split off by conventional methods, so that, just as in the case when E1 in formula (III) stands for hydrogen, the carboxylic acid of formula (I)
-
- in which L and T have the meanings given above,
- is obtained,
or
- [B] by reacting with a compound of formula (V)
-
- E1 stands for hydrogen, (C1-C4)-alkyl or benzyl,
- and
- LA has the meaning of L given above, but is shortened by one CH2 unit in the alkyl chain length,
- in the presence of a suitable reducing agent is converted to a compound of formula (VI)
-
- in which E1, LA and T have the meanings given above,
- and then in the case when E1 stands for (C1-C4)-alkyl or benzyl, this ester radical is split off by conventional methods, so that, just as in the case when E1 in formula (V) stands for hydrogen, the carboxylic acid of formula (I-A)
-
- in which LA and T have the meanings given above,
- is obtained,
and the resulting compounds of formulas (I) and/or (I-A) are optionally separated into their enantiomers and/or diastereomers and/or reacted with the corresponding (i) solvents and/or (ii) bases or acids to form their solvates, salts and/or solvates of the salts.
- Examples of suitable inert solvents for the reaction of (II)+(III)→(IV) include ethers such as diethyl ether, diisopropyl ether, methyl-tert-butylmethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane, heptane, cyclohexane or petroleum fractions or dipolar aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N,N′-dimethylpropylene urea (DMPU), N-methylpyrrolidinone (NMP) or pyridine. It is also possible to use mixtures of such solvents. Acetone or N,N-dimethylformamide is preferred.
- Suitable bases for these alkylation reactions include in particular alkali hydroxides, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali carbonates or alkaline earth carbonates, such as lithium carbonate, sodium carbonate, potassium carbonate, calcium carbonate or cesium carbonate or the usual organic amines such as triethylamine, N-methylmorpholine, N-methylpiperidine, N,N-diisopropylethylamine, pyridine or 4-N,N-dimethylaminopyridine. Potassium or cesium carbonate is preferably used. It is optionally advantageous to add an alkylating catalyst, such as lithium bromide or iodide, sodium or potassium iodide, tetra-n-butylammonium bromide or iodide or benzyltriethylammonium bromide, for example.
- The reaction (II)+(III)→(IV) is generally carried out in a temperature range from −20° C. to +100° C., preferably at 0° C. to +50° C. The reaction may take place at normal, elevated or reduced pressure (e.g., from 0.5 bar to 5 bar). It is usually carried out under normal pressure.
- The reaction (II)+(V)→(VI) takes place in solvents that are inert under the reaction conditions and are typically used for reductive amination, optionally in the presence of an acid and/or a water-withdrawing agent as the catalyst. Such solvents include, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether or other solvents such as dichloromethane, 1,2-dichloroethane, N,N-dimethylformamide or even water Likewise, it is possible to use mixtures of these solvents. The preferred solvent for use here is a 1,4-dioxane/water mixture to which acetic acid or dilute hydrochloric acid is added as a catalyst.
- Suitable reducing agents for this reaction include in particular complex borohydrides, such as sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride or tetra-n-butylammonium borohydride. Sodium cyanoborohydride is preferred.
- The reaction (II)+(V)→(VI) is generally carried out in a temperature range from 0° C. to +120° C., preferably at +50° C. to +100° C. The reaction may take place at normal, elevated or reduced pressure (e.g., from 0.5 bar to 5 bar). It is usually carried out under normal pressure.
- An ester radical E1 is split off by the usual methods in the process steps (IV)→(I) and (VI) [E1=(C1-C4)-alkyl or benzyl] according to the usual methods by treating the ester with an acid or a base in an inert solvent, whereby in the last variant, the carboxylate salt obtained first is converted to the free carboxylic acid by subsequent addition of an acid. In the case of a tert-butyl ester, the cleavage is preferably performed by using an acid. In the case of a benzyl ester, the cleavage may also take place by hydrogenolysis in the presence of a suitable palladium catalyst, such as palladium on activated carbon, for example.
- The ester radical E1 originating from compound (III) and/or (V) is selected here so that the conditions of its cleavage are compatible with the respective group T in compounds (IV) and (VI).
- The usual inorganic bases are suitable as the bases for ester hydrolysis. These include in particular alkali hydroxides or alkaline earth hydroxides such as lithium, sodium, potassium or barium hydroxide, or alkali carbonates or alkaline earth carbonates such as sodium, potassium or calcium carbonates. Lithium, sodium or potassium hydroxide is preferred.
- Suitable acids for the ester cleavage reaction include in general sulfuric acid, hydrochloric acid/hydrogen chloride, hydrobromic acid/hydrogen bromide, phosphoric acid, acetic acid, trifluoroacetic acid, toluenesulfonic acid, methanesulfonic acid or trifluoromethanesulfonic acid or mixtures thereof, optionally with the addition of water. Hydrochloric acid or trifluoroacetic acid are preferred in the case of a tert-butyl ester and hydrochloric acid is preferred in the case of a methyl ester.
- Suitable inert solvents for these reactions include water or the organic solvents typically used for ester cleavage. These preferably include low alcohols such as methanol, ethanol, n-propanol or isopropanol, ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane, or other solvents such as dichloromethane, acetone, methyl ethyl ketone, N,N-dimethylformamide or dimethyl sulfoxide. It is also possible to use mixtures of these solvents. In the case of a basic ester hydrolysis, mixtures of water with 1,4-dioxane, tetrahydrofuran, methanol, ethanol and/or dimethylformamide are preferred for use here. In the case of the reaction with trifluoroacetic acid, dichloromethane is preferred, and in the case of the reaction with hydrochloric acid, tetrahydrofuran, diethyl ether, 1,4-dioxane or water is preferred.
- The ester cleavage generally takes place in a temperature range of −20° C. to +100° C., preferably at 0° C. to +50° C.
- The compounds of formula (II) can be synthesized by the usual methods of peptide chemistry by coupling a compound of formula (VII)
- in which
- PG stands for an amino protective group such as (9H-fluoren-9-ylmethoxy)carbonyl, tert-butoxycarbonyl or benzyloxycarbonyl,
in an inert solvent with activation of the carboxyl function in (VII), either - [C] first with a compound of formula (VIII)
-
- in which
- E2 stands for hydrogen, (C1-C4)-alkyl or benzyl,
- or a salt of this compound to form a compound of formula (IX)
-
- in which E2 and PG have the meanings given above,
- then in the event that E2 stands for (C1-C4)-alkyl or benzyl, this ester radical is split off by the usual methods and the resulting carboxylic acid of formula (X)
-
- in which PG has the meaning given above,
- then in an inert solvent with activation of the carboxyl function with a compound of formula (XI):
-
H2N-T (XI), -
- in which T has the meanings given above,
- or with a salt of this compound to form a compound of formula (XII)
-
- in which PG and T have the meanings given above,
or
- in which PG and T have the meanings given above,
- [D] with a compound of formula (XIII)
-
- in which T has the meanings given above,
- or with a salt of this compound, likewise to form the compound of formula (XII)
-
- in which PG and T have the meanings given above,
and the compound of formula (XII) is then deprotected in the usual way to form a compound of formula (II)
- in which PG and T have the meanings given above,
-
- in which T has the meanings given above.
- The coupling reactions described above (formation of amide from the respective amine and carboxylic acid components) are performed according to the standard methods of peptide chemistry (see, for example, M. Bodanszky, Principles of Peptide Synthesis, Springer Verlag, Berlin, 1993; M. Bodanszky and A. Bodanszky, The Practice of Peptide Synthesis, Springer Verlag, Berlin, 1984; H. D. Jakubke and H. Jeschkeit, Aminosäuren, Peptide, Proteine [Amino Acids, Peptides, Proteins], Verlag Chemie, Weinheim, 1982).
- Inert solvents for these coupling reactions (VII)+(VIII)→(IX), (X)+(XI)→(XII) and (VII), (XIII)→(XII) include, for example, ethers such as diethyl ether, diisopropyl ether, tert-butylmethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis-(2-methoxyethyl)ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane, heptane, cyclohexane or petroleum fractions, halohydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, 1,2-dichloroethane, trichloroethylene or chlorobenzene or dipolar aprotic solvents such as acetone, methyl ethyl ketone, acetonitrile, ethyl acetate, pyridine, dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N,N′-dimethylpropylene urea (DMPU) or N-methylpyrrolidinone (NMP). It is also possible to use mixtures of such solvents. N,N-Dimethylformamide is preferred.
- Suitable activation/condensation agents for these coupling reactions include, for example, carbodiimides such as N,N′-diethyl, N,N′-dipropyl, N,N′-diisopropyl, N,N′-dicyclohexylcarbodiimide (DCC) or N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), phosgene derivatives such as N,N′-carbonyldiimidazole (CDI) or isobutyl chloroformate, 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulfate or 2-tert-butyl-5-methylisoxazolium perchlorate, acylamino compounds, such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, α-chlorenamines such as 1-chloror-2-methyl-1-dimethylamino-1-propene, phosphorus compounds such as propane phosphonic acid anhydride, cyanophosphonic acid diethyl ester, bis-(2-oxo-3-oxazolidinyl)phosphoryl chloride, benzotriazol-1-yloxy-tris-(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate (PyBOP), or uronium compounds such as O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), 2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TPTU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) or O-(1H-6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TCTU), optionally in combination with additional excipients, such as 1-hydroxybenzotriazole (HOBt) or N-hydroxysuccinimide (HOSu) as well as bases, such as alkali carbonates, e.g., sodium or potassium carbonate or tertiary amine bases, such as triethylamine, N-methylmorpholine, N-methylpiperidine, N,N-diisopropylethylamine, pyridine or 4-N,N-dimethylaminopyridine.
- Within the context of the present invention, the preferred activation/condensation agents for such coupling reactions include N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) in combination with 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), likewise in combination with N,N-diisopropylethylamine.
- The coupling reactions (VII)+(VIII)→(IX), (X)+(XI)→(XII) and (VII)+(XIII)→(XII) are usually performed in a temperature range from −20° C. to +60° C., preferably at 0° C. to +40° C. The reactions may be performed under normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). It is customary to work under normal pressure.
- The functional groups optionally present in the compounds—such as amino, hydroxyl and carboxyl groups in particular—may also, if expedient or necessary, be present in a temporarily protected form in the process steps described above. Such protective groups are introduced and removed according to the standard methods of peptide chemistry (see, for example, T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Wiley, New York, 1999; M. Bodanszky and A. Bodanszky, The Practice of Peptide Synthesis, Springer Verlag, Berlin, 1984). In the presence of several protected groups, they may optionally be released again simultaneously in either a one-pot reaction or in separate reaction steps.
- The preferred amino protective group is tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Z) or (9H-fluoren-9-ylmethoxy)carbonyl (Fmoc); tert-butyl or benzyl is preferably used as the protective group PG2 for a hydroxyl or carboxyl function. A tert-butyl or tert-butoxycarbonyl group is usually split off by treating it with a strong acid such as hydrochloric acid, hydrobromic acid or trifluoroacetic acid in an inert solvent such as diethyl ether, 1,4-dioxane, dichloromethane or acetic acid. This reaction may optionally also be performed without adding an inert solvent. In the case of benzyl or benzyloxycarbonyl as the protective group, such a protective group is preferably removed by hydrogenolysis in the presence of a suitable palladium catalyst, such as palladium on activated carbon, for example. The (9H-fluoren-9-ylmethoxy)carbonyl group is generally split off with the help of a secondary amine base, such as diethylamine or piperidine.
- An ester radical E2 in compound (VIII) [E2=(C1-C4)-alkyl or benzyl] here is selected so that the conditions of its being split off are compatible with the respective protective group PG from compound (VII).
- The compounds of formula (VII) can be synthesized by a similar method, for example, by first coupling N-(benzyloxycarbonyl)-L-valine of formula (XIV)
- in which Z stands for the benzyloxycarbonyl protective group,
with a compound of formula (XV) with the help of a condensation agent: - in which E3 stands for (C1-C4)-alkyl,
or with a salt of this compound to form a compound of formula (XVI) - in which E3 and Z have the meanings given above,
then, after hydrogenolytic removal of the Z-protective group, this compound is then coupled with N-protected N-methyl-L-valine of the formula (XVII) in the presence of a condensation agent: - in which
- PG stands for an amino protective group, such as (9H-fluoren-9-ylmethoxy)carbonyl, tert-butoxycarbonyl or benzyloxycarbonyl,
to form a compound of the formula (XVIII) - in which E3 and PG have the meanings given above,
and then the ester group —C(O)O-E3 in (XVIII) is reacted by the usual methods to form the free carboxylic acid (VII). - The coupling reactions (XIV)+(XV)→(XVI) and Z-deprotected (XVI)+(XVII)→(XVIII) are performed under reaction conditions similar to those described above for the coupling steps shown in methods [C] and [D].
- The ester group —C(O)O-E3 is hydrolyzed in reaction step (XVIII)→(VII) in a process similar to that described above as part of the process sequences [A] and [B] for the ester radical E1. The alkyl group E3 in compound (XV) is selected here so that the conditions of their cleavage are compatible with the respective protective group PG from compound (XVII).
- The compounds of formula (XIII) are in turn accessible by coupling the compound (XI) described above with the compound (XIX):
- in which Boc stands for the tert-butoxycarbonyl protective group,
to yield a compound of formula (XX) - in which Boc and T have the meanings given above,
and then splitting off the Boc protective group. - The coupling reaction (XI)+(XIX)→(XX) is in turn performed under similar conditions like those described above for the coupling steps in methods [C] and [D].
- The compounds of formulas (III), (V), (VIII), (XI), (XIV), (XV), (XVII) and (XIX), including chiral or diastereomeric forms thereof, if applicable, are available commercially or have been described as such in the literature or they can be synthesized by methods like those published in the literature in a manner that would be self-evident for those skilled in the art. Numerous detailed publications and specifications in the literature concerning the synthesis of the starting materials can also be found in the Experimental Part in the section on the synthesis of the starting compounds and intermediates.
- If corresponding isomer-pure starting materials are not available, then the compounds according to the invention can expediently be separated into the corresponding enantiomers and/or diastereomers already at the stage of the compounds (II), (IV), (VI), (XI), (XII), (XIII) and (XX), which are then reacted further in isolated form according to the reaction steps described above. Such a separation of the stereoisomers can be performed according to the usual methods familiar to those skilled in the art. Chromatographic methods on chiral and/or achiral separation phases are preferably used. In the case of free carboxylic acids as the intermediates, separation via diastereomeric salts with the help of chiral bases may also be performed as an alternative.
- Synthesis of the compounds according to the invention can be illustrated by the following reaction schemes as an example:
- These compounds have valuable pharmacological properties and can be used for preventing and treating diseases humans and animals.
- In comparison with other auristatin derivatives known from the prior art, the N-terminal carboxyalkyl group [HOOC-L- in formula (I)] present in the compounds according to the present invention does not have the mere function of a linker for the potential linkage to antibody proteins or other ligands, but instead is a constituent structural element for the surprisingly advantageous profile of properties of these compounds.
- These compounds according to the invention have a stronger cytotoxic activity in comparison with monomethylauristatin F (MMAF), for example, or have a reduced potential, while at the same time also being substrates for cellular transporter proteins.
- The compounds according to the invention are therefore particularly suitable for treatment of hyperproliferative diseases in humans and mammals in general. These compounds can on the one hand inhibit, block, reduce or restrict cell proliferation and cell division while increasing apoptosis on the other hand.
- The hyperproliferative diseases for treatment of which the compounds according to the invention may be used include in particular the group of cancers and tumor diseases. These are understood to include in particular the following diseases within the scope of the present invention without being limited to these: breast cancer and breast tumors (ductile and lobular forms, also in situ), respiratory tract tumors (small cell and non-small-cell carcinomas, bronchial carcinoma), brain tumors (e.g., of the brain stem and the hypothalamus, astrocytoma, medulloblastoma, ependymoma and neuroectodermal and pineal tumors), tumors of the digestive tract (esophagus, stomach, gallbladder, small intestine, large intestine, rectum), liver tumors (including hepatocellular carcinoma, cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma), tumors of the head and neck area (larynx, hypopharynx, nasopharynx, oropharynx, lips and oral cavity), skin tumors (squamous epithelial carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer and non-melanoma type skin cancer), tumors of the soft tissues (including soft tissue sarcomas, malignant fibrous histiocytoma, lymphosarcoma and rhabdomyosarcoma), tumors of the eyes (including intraocular melanoma and retinoblastoma), tumors of the endocrine and exocrine glands (e.g., thyroid and parathyroid glands, pancreatic gland and esophageal gland), tumors of the urinary tract (bladder, penis, kidney, renal pelvis and urethral tumors) as well as tumors of the reproductive organs (endometrium, cervical, ovarian, vaginal, vulval and uterine carcinomas in the woman and prostatic and testicular carcinomas in males). These also include proliferative blood diseases in solid form and as circulating blood cells such as lymphomas, leukemias and myeloproliferative diseases, e.g., acute myeloid leukemia, acute lymphoblastic, chronic lymphocytic leukemia, chronic myelogenous leukemia and hairy cell leukemia as well as AIDS-related lymphomas, Hodgkin's lymphomas, non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, Burkitt's lymphomas and lymphomas of the central nervous system.
- These human diseases, which have been characterized well, may also occur with a comparable etiology in other mammals and can also be treated with the compounds according to the present invention in those cases.
- Treatment of the types of cancer mentioned above by means of the compounds according to the invention includes treatment of such tumors as well as treatment of metastatic or circulating forms thereof.
- The terms “treatment” or “to treat” are used in the conventional sense within the scope of this invention and refers to the care, treatment and consultation of a patient with the goal of combatting, reducing, diminishing or ameliorating a disease or health deviation and improving the quality of life, which is impaired by this disease, such as in a cancer, for example.
- An additional subject matter of the present invention thus relates to the use of the compounds according to the invention for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is the use of the compounds according to the invention for producing a pharmaceutical drug for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is the use of the compounds according to the invention in a method for treatment and/or prevention of diseases, in particular the diseases cited above.
- An additional subject matter of the present invention is a method for treatment and/or prevention of diseases, in particular the diseases cited above, using an effective amount of at least one of the compounds according to the invention.
- The compounds according to the invention may be used alone or, if necessary, in combination with one or more other pharmacologically active substances, as long as this combination does not lead to adverse effects and unacceptable side effects. Another subject matter of the present invention therefore relates to pharmaceutical drugs containing at least one of the compounds according to the invention and one or more additional active ingredients, in particular for treating and/or preventing the diseases listed above.
- The compounds according to the invention may be combined with known anti-hyperproliferative, cytostatic or cytotoxic substances, for example, for treatment of cancer. Examples of suitable combination drugs include the following:
- aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, amino glutethimide, amifostine, amrubicin, amsacrine, anastrozol, anzmet, aranesp, arglabin, arsentrioxide, aromasine, 5-azacytidine, azathioprine, BCG or tice-BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine, bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, clodronic acid, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunoxome, decadrone, decadrone phosphate, delestrogen, denileukin diftitox, depo medrol, desloreline, dexrazoxane, diethylstilbestrol, diflucan, docetaxel, doxifluridine, doxorubicin, dronabinol, DW-166HC, eligard, elitek, ellence, emend, epirubicin, epoetin alfa, epogen, eptaplatin, ergamisole, estrace, estradiol, estramustine sodium phosphate, ethinyl estradiol, ethyol, etidronic acid, etopophos, etoposide, fadrozole, farstone, filgrastim, finasteride, fligrastim, floxuridine, fluconazole, fludarabin, 5-fluorodeoxyuridine monophosphate, 5-fluorouracil (5-FU), fluoxymesterone, flutamide, formestane, fosteabine, fotemustine, fulvestrant, gammagard, gemcitabine, gemtuzumab, gleevec, gliadel, gosereline, granisetrone hydrochloride, histreline, hycamtine, hydrocortone, erythrohydroxynonyladenine, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, interferon-alpha, interferon-alpha-2, interferon-alpha-2α, interferon-alpha-2β, interferon-alpha-n1, interferon-alpha-n3, interferon-beta, interferon-gamma-1α, interleukin-2, intron A, iressa, irinotecan, kytril, lentinane sulfate, letrozole, leucovorine, leuprolide, leuprolide acetate, levamisole, levofolic acid calcium salt, levothroid, levoxyl, lomustine, lonidamine, marinol, mechlorethamine, mecobalamine, medroxyprogesterone acetate, megestrole acetate, melphalane, menest, 6-mercaptopurine, mesna, methotrexate, metvix, miltefosine, minocycline, mitomycin C, mitotane, mitoxantrone, modrenal, myocet, nedaplatin, neulasta, neumega, neupogen, nilutamide, nolvadex, NSC-631570, OCT-43, octreotide, ondansetrone hydrochloride, orapred, oxaliplatin, paclitaxel, pediapred, pegaspargase, pegasys, pentostatin, picibanil, pilocarpine hydrochloride, pirarubicin, plicamycin, porfimer sodium, prednimustin, prednisolone, prednisone, premarin, procarbazine, procrit, raltitrexed, rebif, rhenium 186 etidronate, rituximab, roferone A, romurtide, salagen, sandostatin, sargramostim, semustine, sizofiran, sobuzoxane, solu-medrol, streptozocin, strontium-89 chloride, synthroid, tamoxifen, tamsulosine, tasonermine, tastolactone, taxoter, teceleukin, temozolomide, teniposide, testosterone propionate, testred, thioguanine, thiotepa, thyro-tropin, tiludronic acid, topotecan, toremifen, tositumomab, tastuzumab, teosulfane, tre-tinoin, trexall, trimethylmelamine, trimetrexate, triptoreline acetate, triptoreline pamoate, uft, uridine, valrubicin, vesnarinone, vinblastine, vincristine, vindesine, vinorelbine, virulizine, zinecard, zinostatin stimalamer, zofran; ABI-007, acolbifene, actimmune, affinitak, aminopterine, arzoxifene, asoprisnil, atamestane, atrasentane, avastin, BAY 43-9006 (sorafenib), CCI-779, CDC-501, celebrex, cetuximab, crisnatol, cyproterone acetate, decitabin, DN-101, doxorubicin MTC, dSLIM, dutasteride, edotecarin, eflornithine, exatecane, fenretinide, histamine dihydrochloride, histreline-hydrogel implant, holmium-166-DOTMP, ibandronic acid, interferon-gamma, intron PEG, ixabepilone, keyhole limpet hemocyanine, L-651582, lanreotide, lasofoxifen, libra, lona-farnib, miproxifen, minodronate, MS-209, liposomales MTP-PE, MX-6, nafareline, nemorubicin, neovastat, nolatrexed, oblimersen, onko-TCS, osidem, paclitaxel polyglutamate, pamidronate disodium, PN-401, QS-21, quazepam, R-1549, raloxifene, ranpirnase, 13-cis-retinic acid, satraplatin, seocalcitol, T-138067, tarceva, taxoprexine, thymosine-alpha-1, tiazofurine, tipifarnib, tirapazamine, TLK-286, toremifene, transmid 107R, valspodar, vapreotide, vatalanib, verteporfin, vinflunine, Z-100, zoledronic acid as well as combinations thereof.
- In a preferred embodiment, the compounds according to the present invention may be combined with antihyperproliferative agents, which may include the following, for example, although this list is not conclusive:
- aminoglutethimide, L-asparaginase, azathioprine, 5-azacytidine, bleomycin, busulfan, carboplatin, carmustin, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, 2′,2′-difluorodeoxycytidine, docetaxel, doxorubicin (adriamycin), epirubicin, epothilone and seine derivate, erythrohydroxynonyladenine, ethinyl estradiol, etoposide, fludarabine phosphate, 5-fluorodeoxyuridine, 5-fluordeoxyuridine monophosphate, 5-fluoruracil, fluoxymesterone, flutamide, hexamethyl melamine, hydroxyurea, hydroxyprogesterone caproate, idarubicin, ifosfamide, interferon, irinotecan, leucovorin, lomustine, mechlorethamine, medroxyprogesterone acetate, megestrol acetate, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitotane, mitoxantrone, paclitaxel, pentostatin, n-phosphonoacetyl L-aspartate (PALA), plicamycin, prednisolone, prednisone, procarbazine, raloxifene, semustine, streptozocin, tamoxifen, teniposide, testosterone propionate, thioguanine, thiotepa, topotecan, trimethylmelamine, uridine, vinblastine, vincristine, vindesine and vinorelbine.
- According to one very promising feature, the compounds according to the invention can also be combined with biological therapeutic agents such as antibodies (e.g., Avastin, Rituxan, Erbitux, Herceptin). The compounds according to the invention may also achieve positive effects in combination with treatments directed against angiogenesis, for example, with Avastin, axitinib, recentin, regorafenib, sorafenib or sunitinib. Combinations with inhibitors of the proteasome and of mTOR as well as combinations with antihormones and steroidal metabolic enzyme inhibitors are also especially suitable because of their favorable profile of side effects.
- In general, the following goals can be pursued with the combination of compounds of the present invention with other active cytostatic or cytotoxic agents:
-
- improved efficacy in retarding the growth of a tumor, reducing its size or even completely eliminating it in comparison with treatment with a single drug;
- the possibility of using the chemotherapeutic drugs in a lower dose than in monotherapy;
- the possibility of a tolerable therapy with few adverse effects in comparison with a single dose;
- the possibility of treatment of a broader spectrum of tumors;
- achieving a higher response rate to the treatment;
- longer survival time for patients in comparison with today's standard therapy.
- In addition, the compounds according to the invention may also be used in combination with radiation therapy and/or a surgical intervention.
- Another subject matter of the present invention relates to pharmaceutical drugs containing at least one compound according to the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients as well as their use for the purposes indicated above.
- The compounds according to the invention may can systemically and/or topically. To this end, they are administered by a suitable route, for example, by an oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, transdermal, conjunctival or otic route or as an implant and/or a stent.
- For these methods of administration, the compounds according to the invention may be administered in suitable dosage forms.
- For oral administration, the suitable dosage forms that function according to the state of the art and deliver the compounds according to the invention rapidly and/or in a modified form contain the compounds according to the invention in a crystalline and/or amorphized and/or dissolved form, e.g., tablets (coated or uncoated tablets, for example, with enteric coatings or insoluble coatings or those with a delayed release that control the release of the compound according to the invention), tablets or films/oblates that disintegrate rapidly in the mouth, films/lyophilisates, capsules (for example, hard or soft gelatin capsules), coated pills, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
- Parenteral administration may be used to bypass a resorption step (e.g., intravenous, intra-arterial, intracardiac, intraspinal or intralumbar) or with the inclusion of resorption (e.g., intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Suitable dosage forms for parenteral administration include infusion and injection preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
- For the other routes of administration, it is suitable to use inhalation dosage forms (including powder inhalers, nebulizers), nose drops, solutions or sprays, tablets to be administered lingually, sublingually or buccally, films, oblates or capsules, suppositories, ear or eye preparations, vaginal suppositories, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g., patches), milks, pastes, foams, dusting powders, implants or stents.
- Oral or parenteral administration is preferred, in particular oral and intravenous administration.
- The compounds according to the invention may be converted to the dosage forms indicated. This may be done in a known way by mixing with inert, non-toxic, pharmaceutically suitable excipients. These excipients include, among others, vehicles (for example, microcrystalline cellulose, lactose, mannitol), solvents (e.g., liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example, sodium dodecyl sulfate, polyoxysorbitan oleate), binders (for example, polyvinyl pyrrolidone), synthetic and natural polymers (for example, albumin), stabilizers (e.g., antioxidants such as ascorbic acid), coloring agents (e.g., inorganic pigments such as iron oxides, for example) and taste and/or odor correcting substances).
- For parenteral administration in general, it has proven advantageous to administer doses of approx. 0.001 to 1 mg/kg, preferably approx. 0.01 to 0.5 mg/kg body weight to achieve effective results. In oral administration, the dose is approx. 0.01 to 100 mg/kg, preferably approx. 0.01 to 20 mg/kg and most especially preferably 0.1 to 10 mg/kg body weight.
- Nevertheless, it may optionally be necessary to deviate from the stated amounts, namely depending on body weight, route of administration, individual response to the active ingredient, type of administration and time or interval in which the substance is administered. This in some cases it may be sufficient to use less than the aforementioned minimum dose, whereas in other cases the aforementioned upper limit must be exceeded. In the case of administration of larger doses, it may be advisable to divide them into multiple individual doses distributed throughout the day.
- The following exemplary embodiments illustrate the invention. The invention is not limited to these examples.
- The percentage amounts in the following tests and examples are percent by weight, unless otherwise indicated. Parts are parts by weight. Solvent ratios, dilution ratios and concentration data on liquid/liquid solutions are each based on volume.
-
- abs. absolute
- Ac acetyl
- aq. aqueous, aqueous solution
- Boc tert-butoxycarbonyl
- br. wide (in NMR)
- sp. example
- ca. circa, approx.
- CI chemical ionization (in MS)
- d doublet (in NMR)
- d day(s)
- TLC thin-layer chromatography
- DCI direct chemical ionization (in MS)
- dd doublet of doublet (in NMR)
- DMAP 4-N,N-dimethylaminopyridine
- DME 1,2-dimethoxyethane
- DMF N,N-dimethylformamide
- DMSO dimethyl sulfoxide
- DPBS Dulbecco's phosphate-buffered saline solution
- dt doublet of triplet (in NMR)
- theor. of the theoretical
- EDC N′-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
- EI electron collision ionization (in MS)
- eq. equivalent(s)
- ESI electron spray ionization (in MS)
- FCS fetal calf serum
- Fmoc (9H-fluoren-9-ylmethoxy)carbonyl
- GC-MS gas chromatography-linked mass spectrometry
- sat. saturated
- GTP guanosine 5′-triphosphate
- h hour(s)
- HATU O-(7-azabenzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate
- HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
- HOAc acetic acid
- HOBt 1-hydroxy-1H-benzotriazole hydrate
- HOSu N-hydroxysuccinimide
- HPLC high-pressure, high-performance liquid chromatography
- HR-MS high-resolution mass spectrometry
- conc. concentrated
- LC-MS liquid chromatography-linked mass spectrometry
- m multiplet (in NMR)
- min minute(s)
- MS mass spectrometry
- MTBE methyl-tert-butyl ether
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
- NMM N-methylmorpholine
- NMP N-methyl-2-pyrrolidinone
- NMR nuclear magnetic resonance spectrometry
- PBS phosphate-buffered saline solution
- Pd/C palladium on activated carbon
- quant. quantitative (in yield)
- quart quartet (in NMR)
- quint quintet (in NMR)
- Rf retention index (in TLC)
- RT room temperature
- Rt retention time (in HPLC)
- singled (in NMR)
- t triplet (in NMR)
- tert tertiary
- TFA trifluoroacetic acid
- THF tetrahydrofuran
- UV ultraviolet spectrometry
- v/v volume to volume ratio (of a solution)
- Z benzoxycarbonyl
- tog. together
- Instrument: Waters Acquity SQD UPLC system; column: Waters Acquity UPLC HSS T3 1.8μ 50 mm×1 mm; eluent A: 1 liter water+0.25 mL 99% formic acid; eluent B: 1 liter acetonitrile+0.25 mL 99% formic acid; gradient: 0.0 min 90% A→1.2 min 5% A→2.0 min 5% A; flow rate: 0.40 mL/min; oven: 50° C.; UV detection: 210-400 nm.
- Instrument: Micromass Quattro Premier with Waters UPLC Acquity; column: Thermo Hypersil GOLD 1.9μ 50 mm×1 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 90% A→0.1 min 90% A→1.5 min 10% A→2.2 min 10% A; flow rate: 0.33 mL/min; oven: 50° C.; UV detection: 210 nm.
- Instrument: Micromass Quattro Micro MS with HPLC Agilent series 1100; column: Thermo Hypersil GOLD 3μ 20 mm×4 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 100% A→3.0 min 10% A→4.0 min 10% A→4.01 min 100% A (flow rate: 2.5 mL/min)->5.00 min 100% A; oven: 50° C.; flow rate: 2 mL/min; UV detection: 210 nm.
- Instrument type MS: Micromass ZQ; instrument type HPLC: HP 1100 series; UV DAD; column: Phenomenex Gemini 3μ 30 mm×3.00 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 90% A→2.5 min 30% A→3.0 min 5% A→4.5 min 5% A; flow rate: 0.0 min 1 mL/min)->2.5 min/3.0 min/4.5 min 2 mL/min; oven: 50° C.; UV detection: 210 nm.
- Instrument: HP 1090 series II; column: Merck Chromolith Speed ROD RP-18e, 50 mm×4.6 mm; precolumn: Merck Chromolith guard Cartridge Kit RP-18e, 5 mm×4.6 mm; injection volume: 5 μL; eluent A: 70% HClO4 in water (4 mL/L); eluent B: acetonitrile; gradient: 0.00 min 20% B→4.00 min 20% B; flow rate: 5 mL/min; column temperature: 40° C.
- Instrument: Waters 2695 with DAD 996; column: Merck Chromolith Speed ROD RP-18e, 50 mm×4.6 mm; precolumn: Merck Chromolith Guard Cartridge Kit RP-18c, 5 mm×4.6 mm; eluent A: 70% HCLO4 in water (4 mL/L); eluent B: acetonitrile; gradient: 0.00 min 5% B→3.00 min 95% B→4.00 min 95% B; flow rate: 5 mL/min.
- Instrument type: Waters ZQ; instrument type HPLC: Agilent 1100 series; UV DAD; column: Thermo Hypersil GOLD 3μ 20 mm×4 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 100% A→3.0 min 10% A→4.0 min 10% A→4.1 min 100% A (flow rate: 2.5 mL/min); oven: 55° C.; flow rate: 2 mL/min; UV detection: 210 nm.
- Instrument type MS: Waters ZQ; instrument type HPLC: Agilent 1100 series; UV DAD; column: Thermo Hypersil GOLD 3μ 20 mm×4 mm; eluent A: 1 liter water+0.5 mL 50% formic acid; eluent B: 1 liter acetonitrile+0.5 mL 50% formic acid; gradient: 0.0 min 100% A→2.0 min 60% A→2.3 min 40% A→3.0 min 20% A→4.0 min 10% A→4.2 min 100% A (flow rate: 2.5 mL/min); oven: 55° C.; flow rate: 2 mL/min; UV detection: 210 nm.
- Instrument: Waters Acquity SQD UPLC system; column: Waters Acquity UPLC HSS T3 1.8μ 50 mm×1 mm; eluent A: 1 liter water+0.25 mL 99% formic acid; eluent B: 1 liter acetonitrile+0.25 mL 99% formic acid; gradient: 0.0 min 95% A→6.0 min 5% A→7.5 min 5% A; oven: 50° C.; flow rate: 0.35 mL/min; UV detection: 210-400 nm.
- Instrument: Agilent 1200 series; column: Agilent Eclipse XDB-C18 5μ 4.6 mm×150 mm; pecolumn: Phenomenex KrudKatcher disposable precolumn; injection volume: 5 μL; eluent A: 1 liter water+0.01% trifluoroacetic acid; eluent B: 1 liter acetonitrile; gradient: 0.0 min 10% B→1.00 min 10% B→1.50 min 90% B→5.5 min 10% B; flow rate: 2 mL/min; column temperature: 30° C.
- Instrument: Waters Acquity SQD UPLC system; column: Waters Acquity UPLC HSS T3 1.8μ 30 mm×2 mm; eluent A: 1 liter water+0.25 mL 99% formic acid; eluent B: 1 liter acetonitrile+0.25 mL 99% formic acid; gradient: 0.0 min 90% A→1.2 min 5% A→2.0 min 5% A; flow rate: 0.60 mL/min; oven: 50° C.; UV detection: 208-400 nm.
- Instrument: Micromass GCT, GC 6890; column: Restek RTX-35, 15 m×200 μm×0.33 μm; constant flow rate of helium: 0.88 mL/min; oven: 70° C.; inlet: 250° C.; gradient: 70° C., 30° C./min→310° C. (3 min hold).
- Instrument: Thermo Scientific LTQ Orbitrap XL; FTMS ESI Positive
- All reactants and reagents whose preparation procedures are not described explicitly below can be acquired commercially from generally accessible sources. For all other reactants and reagents, whose preparation procedures are also not described below and which were not available commercially or which were acquired from sources not generally available, the published literature describing their preparation has been referenced.
-
- The title compound can be synthesized by various methods according to procedures described in the literature; see, e.g., Pettit et al., Synthesis 1996, 719; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913; Koga et al., Tetrahydron Lett. 1991, 32, 2395; Vidal et al., Tetrahedron 2004, 60, 9715; Poncet et al., Tetrahedron 1994, 50, 5345. It was synthesized here according to the procedure by Shioiri et al. (Tetrahedron Lett. 1991, 32, 931).
-
- The title compound can be synthesized by various methods described in the literature; see, e.g., Pettit et al., J. Org. Chem. 1994, 59, 1796; Koga et al., Tetrahedron Lett. 1991, 32, 2395; Shioiri et al., Tetrahedron Lett. 1991, 32, 931; Shioiri et al., Tetrahedron 1993, 49, 1913. It was synthesized here according to the procedure by Koga et al. (Tetrahedron Lett. 1991, 32, 2395).
-
- 425 mg (1.7 mmol) N-[(benzyloxy)carbonyl]-L-valine was dissolved in 50 mL DMF and mixed in succession with 500 mg (1.7 mmol) tert-butyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino) heptanoate hydrochloride (starting compound 2), 356 mg (1.9 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 285 mg (1.9 mmol) 1-hydroxy-1H-benzotriazole hydrate and 655 mg (5.1 mmol) N,N-diisopropylethylamine. The mixture was stirred for 20 hours at RT. Then 142 mg (0.5 mmol) N-Rbenzyloxy)-carbonyl]-L-valine, 119 mg (0.6 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 95 mg (0.6 mmol) 1-hydroxy-1H-benzotriazole hydrate and 218 mg (1.7 mmol) N,N-diisopropylemethylamine were also added, and the mixture was treated ultrasonically for 90 min. The batch was then poured into a mixture of 50% saturated aqueous ammonium chloride solution and ethyl acetate. The organic phase was separated, then washed with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated. The residue was then purified by preparative HPLC, yielding 329 mg (40% of the theoretical) of the title compound as a colorless oil.
- HPLC (method 5): Rt=2.5 min;
- LC-MS (method 1): Rt=1.45 min; MS (ESIpos): m/z=493 (M+H)+.
-
- 500 mg (1 mmol) tert-Butyl-(3R,4S,5S)-4[{N-[(benzyloxy)carbonyl]-(L-valyl}(methyl)-amino]-3-methoxy-5-methylheptanoate (intermediate 1) was dissolved in 50 mL methanol and hydrogenated for one hour at RT under normal pressure after adding 100 mg 10% palladium on activated carbon. The catalyst was then filtered out and the solvent was removed in vacuo, yielding 370 mg (quantitative) of the title compound as an almost colorless oil.
- HPLC (method 5): Rt=1.59 min;
- LC-MS (method 1): Rt=0.74 min; MS (ESIpos): m/z=359 (M+H)+.
-
- 396 mg (1.1 mmol) N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valine was dissolved in DMF and then mixed in succession with 365 mg (1 mmol) tert-butyl-(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl(L-valyl)amino]heptanoate (intermediate 2), 234 mg (1.2 mmol) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 187 mg (1.2 mmol) 1-hydroxy-1H-benzotriazole hydrate. The mixture was stirred over night at RT. The batch was then poured into a mixture of 50% saturated aqueous ammonium chloride solution and ethyl acetate. The organic phase was separated, washed in succession with saturated sodium bicarbonate solution and saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated. The residue was used directly in the next step without further purification.
- Yield: 660 mg (68% of the theoretical)
- HPLC (method 5): Rt=3.0 min;
- LC-MS (method 1): Rt=1.61 min; MS (ESIpos): m/z=694 (M+H)+.
-
- 650 mg (0.94 mmol) N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-1-tert-butoxy-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 3) was dissolved in 5 mL dichloromethane, mixed with 5 mL trifluoroacetic acid and stirred over night at RT. Then the mixture was concentrated in vacuo, and the remaining residue was purified by preparative HPLC, yielding 430 mg (72% of the theoretical) of the title compound as a colorless foam.
- HPLC (method 5): Rt=2.4 min;
- LC-MS (method 2): Rt=1.51 min; MS (ESIpos): m/z=638 (M+H)+.
-
- 51 mg (0.08 mmol) N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methylhexan-3-yl]-N-methyl-L-valinamide (intermediate 4) was dissolved in 10 mL DMF and mixed with 0.5 mL piperidine. After stirring for 10 min at RT, the batch was concentrated in vacuo and the residue was stirred with diethyl ether. The insoluble ingredients were filtered out and washed several times with diethyl ether. Then the filter residue was dissolved in 5 mL dioxane/water (1:1) and the solution was adjusted to pH 11 with 1N sodium hydroxide solution. While treating with ultrasound, a total of 349 mg (1.6 mmol) di-tert-butyl dicarbonate was added in several portions, while the pH of the solution was kept at 11. After the end of the reaction, the dioxane was evaporated and the pH of the aqueous solution was adjusted to 2-3 with citric acid. Extraction was performed twice with 50 mL ethyl acetate each time. The organic phases were combined, dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in diethyl ether and the product was precipitated with pentane. The solvent was separated by decanting. The residue was digested again with pentane and finally dried in a high vacuum, yielding 31 mg (93% of the theoretical) of the title compound.
- HPLC (method 6): Rt=2.2 min;
- LC-MS (method 2): Rt=1.32 min; MS (ESIpos): m/z=516 (M+H)+.
-
- First, (2R,3R)-3-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-3-methoxy-2-methyl-propanoic acid was released from 1.82 g (3.88 mmol) of the dicyclohexylamine salt (starting compound 1) by dissolving it in 150 mL ethyl acetate and extracting with 100 mL 0.5% aqueous sulfuric acid. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was dissolved in 10 mL dioxane and 10 mL water, mixed with 1517 mg (4.66 mmol) cesium carbonate and treated for 5 min in an ultrasonic bath. It was then concentrated in vacuo and the residue was co-distilled once with DMF. The residue was then dissolved in 15 mL DMF and mixed with 1990 mg (11.64 mmol) benzyl bromide. The mixture was treated in an ultrasonic bath for 15 min and then concentrated in vacuo. The residue was distributed between ethyl acetate and water. The organic phase was separated, washed with sodium chloride solution and then concentrated. The residue was finally purified by preparative HPLC, thereby yielding 1170 mg (80% of the theoretical) of the Boc-protected intermediate tert-butyl-(2S)-2-[(1R,2R)-3-(benzyloxy)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidine-1-carboxylate.
- This 1170 mg of the intermediate was immediately dissolved in 15 mL dichloromethane and mixed with 5 mL trifluoroacetic acid. After stirring for 15 min at RT, the batch was concentrated in vacuo and the residue was lyophilized from dioxane. After drying in a high vacuum, there remained 1333 mg (84% of the theoretical) of the title compound as a yellow oil.
- HPLC (method 5): Rt=1.5 min;
- LC-MS (method 1): Rt=0.59 min; MS (ESIpos): m/z=278 (M+H)+.
-
- 1200 mg (2.33 mmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(2R,3S,4S)-1-carboxy-2-methoxy-4-methyl-hexan-3-yl]-N-methyl-L-valinamide (intermediate 5) was combined with 910.8 mg (2.33 mmol) benzyl-(2R,3R)-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanoate trifluoroacetic acid salt (intermediate 6), 1327 mg (3.49 mmol) O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate and 2027 μL N,N-diisopropylethylamine in 50 mL DMF and stirred for 5 min at RT. Next the solvent was removed in vacuo. The remaining residue was dissolved in ethyl acetate and then extracted with 5% aqueous citric acid solution and saturated sodium bicarbonate solution in succession. The organic phase was separated and concentrated. The residue was purified by preparative HPLC. The product fractions were combined, concentrated and the residue was dried in a high vacuum, yielding 1000 mg (55% of the theoretical) of the benzyl ester intermediate N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-benzyloxy)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valin-amide as a resin.
- LC-MS (method 1): Rt=1.56 min; MS (ESIpos): m/z=775 (M+H)+.
- The total amount of the intermediate obtained was dissolved in 25 mL of a mixture of methanol and dichloromethane (20:1) and the benzyl ester group was removed by hydrogenation under normal pressure with 10% palladium on activated carbon as the catalyst. After stirring for 30 min at RT, the catalyst was filtered out and the filtrate was concentrated in vacuo, yielding 803 mg (91% of the theoretical) of the title compound as a white solid.
- HPLC (method 5): Rt=2.1 min;
- LC-MS (method 1): Rt=1.24 min; MS (ESIpos): m/z=685 (M+H)+.
-
- 1000 mg (3.77 mmol) N-(tert-butoxycarbonyl)-L-phenylalanine was placed in 10 mL dichloromethane and mixed with 733 mg (4.52 mmol) 1,1′-carbonyldiimidazole. The batch was stirred for 15 min until the evolution of gas had stopped. Next the mixture was mixed with 441 mg (4.52 mmol) N,O-dimethylhydroxylamine hydrochloride and 657 μL (3.77 mmol) N,N-diisopropylethylamine and stirred for 1 hour at RT. Next the batch was diluted with dichloromethane and washed with distilled water, 0.5N hydrochloric acid and saturated sodium chloride solution in succession. The organic phase was separated and the combined aqueous phases were re-extracted with ethyl acetate. The combined organic phases were dried over magnesium sulfate and concentrated in vacuo, yielding 1090 mg (93% of the theoretical) of the title compound.
- LC-MS (method 1): Rt=1.02 min; MS (ESIpos): m/z=309 (M+H)+.
-
- 1090 mg (3.5 mmol) Nα-(tert-butoxycarbonyl)-N-methoxy-N-methyl-L-phenylalanine-amide was dissolved in 20 mL 2-methyltetrahydrofuran and cooled to 0° C. Then 4.2 mL (4.2 mmol) of a 1M lithium aluminum hydride solution was added slowly to THF, and the reaction mixture was stirred for 30 min at 0° C. Next 5% aqueous potassium hydrogen sulfate solution was added cautiously. The batch was then diluted with water and extracted with MTBE. The organic phase was dried over magnesium sulfate and concentrated in vacuo, yielding 820 mg (94% of the theoretical) of the title compound.
- GC-MS (method 12): Rt=5.61 mm; MS (ESIpos): m/z=220 (M−29)+
- 1H-NMR (500 MHz, DMSO-d6): δ [ppm]=1.15-1.42 (m, 9H), 7.11-7.39 (m, 5H), 9.52 (s, 1H) [additional signals concealed beneath solvent peaks]
-
- Under argon, 842 μL (2.1 mmol) 2.5 M n-butyllithium solution in hexane was added to a suspension of 986 mg (2.2 mmol) triphenyl-(2-phenylethyl)phosphonium bromide [can be synthesized, e.g., according to R. W. Hartmann, M. Reichert, Archiv der Pharmazie 333, 145 (2000); K. C. Nicolaou et al., European J. Chem. 1, 467 (1995)] in 125 mL THF at −78° C., and the mixture was then stirred for one hour at 0° C. The reaction mixture was then cooled back to −78° C. and a solution of 500 mg (2.0 mmol) tert-butyl-[(2S)-1-oxo-3-phenylpropan-2-yl]carbamate in 5 mL dry THF was added. The batch was heated to 0° C. and stirred further for three hours at this temperature. The reaction was then terminated by adding saturated aqueous ammonium chloride solution. The mixture was diluted with MTBE, the phases were separated, and the organic phase was dried over magnesium sulfate and concentrated in vacuo. The residue was purified over a silica gel column using cyclohexane/ethyl acetate 5:1 as the mobile phase. After concentrating the corresponding fractions, 173 mg (25.6% of the theoretical) of the Boc-protected intermediate, tert-butyl-[(2S,3Z)-1,5-diphenylpent-3-en-2-yl]carbamate was obtained.
- 1H-NMR (400 MHz, DMSO-d6): δ [ppm]=1.16-1.46 (m, 9H), 2.62 (dd, J=13.20 Hz, 7.34 Hz, 1H), 2.73-3.18 (m, 1H), 4.56 (t, J=7.46 Hz, 1H), 5.27-5.57 (m, 1H), 6.98-7.32 (m, 10H) [additional signals concealed beneath solvent peaks].
- 173 mg (512 μmol) of the intermediate tert-butyl[2S,3Z)-1,5-diphenylpent-3-en-2-yl]carbamate was placed in 16 mL dichloromethane, mixed with 4 mL trifluoroacetic acid and left to stand for 30 min at RT. Next the reaction mixture was concentrated and the residue was dried in vacuo, yielding 180 mg (99% of the theoretical) of the title compound.
- LC-MS (method 1): Rt=0.74 min; MS (ESIpos): m/z=238 (M+H)+.
- 1H-NMR (400 MHz, DMSO-d6): δ [ppm]=2.64-2.83 (m, 1H), 2.88-3.22 (m, 2H), 4.00-4.55 (m, 1H), 5.16-5.46 (m, 1H), 5.48-5.78 (m, 1H), 6.60-6.89 (m, 2H), 7.14 (s, 3H), 7.22-7.36 (m, 5H), 7.89-8.27 (m, 2H).
-
- 200 mg (1.13 mmol) (4S)-4-benzyl-1,3-benzyl-1,3-oxazolidin-2-one was placed in 3 mL tert-butanol and mixed with 280 mg (2.26 mmol) benzylmercaptan. The mixture was then heated at reflux for two days. Then the batch was concentrated on the rotary evaporator and the resulting intermediate (2S)-1-(benzylsulfanyl)-3-phenylpropan-2-amine was reacted further without workup.
- HPLC (method 10): Rt=2.63 min;
- LC-MS (method 1): Rt=0.67 min; MS (ESIpos): m/z=258 (M+H)+.
- The crude intermediate obtained above was dissolved in a solution of 2 mL 30% hydrogen peroxide and 5 mL formic acid and stirred for 12 h at RT. Then the reaction mixture was poured into saturated aqueous sodium sulfate solution and extracted three times with ethyl acetate. The organic phase was dried over magnesium sulfate and concentrated in vacuo. The resulting raw product was purified by preparative HPLC, thus yielding 343 mg (61% of the theoretical) of the title compound.
- HPLC (method 10): Rt=2.40 min;
- LC-MS (method 1): Rt=0.65 min; MS (ESIpos): m/z=290 (M+H)+.
-
- 552.7 mg (9.85 mmol) potassium hydroxide was dissolved in methanol, absorbed onto 1.1 g aluminum oxide and then dried in a high vacuum. At 5-10° C., 307 μL (3.3 mmol) dibromodifluoromethane was added by drops to a solution of 240 mg (0.82 mmol) (2S)-1-benzylsulfonyl)-3-phenylpropan-2-amine and 1.56 g of the potassium hydroxide prepared in this way on aluminum oxide in 6.2 mL n-butanol. The reaction mixture was stirred for two hours at RT, then filtered through Celite, and the residue was rewashed well with dichloromethane. The filtrate was concentrated and the resulting residue was dried in vacuo. The resulting raw produce was purified by preparative HPLC, yielding 98 mg (35% of the theoretical) of the title compound with an E/Z diasteromer ratio of 4:1.
- HPLC (method 10): Rt=2.46 min;
- LC-MS (method 1): Rt=0.75 min; MS (ESIpos): m/z=224 (M+H)+.
- The E/Z diastereomer mixture obtained above was dissolved in 2 mL ethanol and 0.2 mL N,N-diisopropylethylamine and separated over HPLC on a chiral phase [column: Daicel Chiralpak AD-H, 5 μm, 250 mm×20 mm; eluent: hexane/(ethanol+0.2% diethylamine) 50:50 v/v; UV detection: 220 nm; temperature: 30° C.]. The corresponding fractions were concentrated on a rotary evaporator and the residue was dried in vacuo, yielding 10 mg of the title compound as a pure Z isomer.
- 1H-NMR (400 MHz, DMSO-d6): δ [ppm]=2.71 (d, J=6.60 Hz, 2H), 3.73-3.95 (m, 1H), 5.42-5.67 (m, 1H), 6.21-6.50 (m, 1H), 7.08-7.38 (m, 10H) [additional signals concealed beneath solvent peaks].
-
- The title compound (pure E isomer) was obtained in a yield of 45 mg in the course of chromatographic diastereomer separation on a chiral phase, as described for intermediate 12.
- 1H-NMR (400 MHz, DMSO-d6): δ [ppm]=2.62-2.83 (m, 2H), 3.52-3.71 (m, 1H), 6.18-6.30 (m, 1H), 6.34-6.46 (m, 1H), 6.98-7.57 (m, 10H) [additional signals concealed beneath solvent peaks].
-
- 200 mg (0.75 mmol) N-(tert-butoxycarbonyl)-L-phenylalanine was placed in 5.5 mL dichloromethane at 0° C. and mixed with 128 mg (0.79 mmol) 1,1′-carbonyldiimidazole. After 30 min, 103 mg (0.75 mmol) benzoyl hydrazide was added. Finally, after 45 min more at 0° C., 500 mg (1.5 mmol) carbon tetrabromide and 395 mg (1.5 mmol) triphenylphosphine were added. The batch was first stirred for 2 h at 0° C. and then stirred over night at RT. The mixture was then concentrated on a rotary evaporator and the residue was dried in a high vacuum. The resulting raw product was purified by preparative HPLC, yielding 217 mg (78% of the theoretical) of the Boc-protected intermediate tert-butyl-[(1S)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate.
- HPLC (method 10): Rt=3.01 min;
- LC-MS (method 1): Rt=1.15 min; MS (ESIpos): m/z=366 (M+H)+.
- 217 mg (0.59 mmol) of this intermediate was dissolved in 3 mL dichloromethane, mixed with 0.6 mL trifluoroacetic acid and stirred for 30 min at RT. Then the mixture was concentrated in vacuo. The remaining residue was dried further in vacuo and then lyophilized from dioxane, thereby yielding 214 mg (90% of the theoretical) of the title compound as a white solid.
- HPLC (method 10): Rt=2.43 min;
- LC-MS (method 1): Rt=0.62 min; MS (ESIpos): m/z=266 (M+H)+.
-
- 200 mg (0.75 mmol) N-(tert-butoxycarbonyl)-D-phenylalanine was placed in 5.5 mL dichloromethane at 0° C. and mixed with 128.3 mg (0.79 mmol) 1,1′-carbonyldiimidazole. After 30 min, 103 mg (0.75 mmol) benzoyl hydrazide was added. Finally, after 45 min more at 0° C., 500 mg (1.5 mmol) carbon tetrabromide and 395 mg (1.5 mmol) triphenylphosphine were added. The batch was first stirred for 2 h at 0° C. and then stirred over night at RT. The mixture was then concentrated on a rotary evaporator and the residue was dried in a high vacuum. The resulting raw product was purified by preparative HPLC, yielding 219 mg (80% of the theoretical) of the Boc-protected intermediate tert-butyl-[(1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]carbamate.
- HPLC (method 10): Rt=3.01 min;
- LC-MS (method 2): Rt=1.36 min; MS (ESIpos): m/z=366 (M+H)+.
- 219 mg (0.6 mmol) of this intermediate was dissolved in 3 mL dichloromethane, mixed with 0.6 mL trifluoroacetic acid and stirred for 30 min at RT. Next the mixture was concentrated in vacuo. The remaining residue was dried further in vacuo and then lyophilized from dioxane, thus yielding 196 mg (86% of the theoretical) of the title compound as a white solid.
- HPLC (method 10): Rt=2.41 min.
-
- 0.9 mg (4 μmol) palladium acetate was placed in 5 mL DMF and then mixed in succession with 20.8 mg (97 μmol) methyl-4-bromobenzoate, 20 mg (81 μmol) (S)-tert-butyl-1-phenylbut-3-en-2-ylcarbamate, 1.1 mg (8 μmol) phenylurea and 11.2 mg (81 μmol) potassium carbonate. The reaction mixture was then stirred for 15 min at 160° C. in a microwave apparatus (Emrys™ Optimizer). The mixture was then filtered and the filtrate was separated into its components by preparative HPLC (eluent: methanol/water gradient with 0.1% TFA), yielding 21.3 mg (68% of the theoretical) of the title compound.
- HPLC (method 10): Rt=3.23 min;
- LC-MS (method 11): Rt=1.32 min; MS (ESIpos): m/z=382 (M+H)+.
-
- 15 mg (22 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) was placed in 750 μL DMF and mixed with 11.44 μL (66 μmol) N,N-diisopropylethylamine and 10 mg (26 μmol HATU. The batch was stirred for 30 min at RT. Then 8.5 mg (24 μmol) (2S,3Z)-1,5-diphenylpent-3-en-2-amine trifluoroacetic acid salt (intermediate 10) was added and the batch was stirred over night at RT. The reaction mixture was then immediately separated into its components by preparative HPLC, yielding 18.1 mg (91% of the theoretical) of the Boc-protected intermediate N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3Z)-1,5-diphenylpent-3-en-2-yl]amino)-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide in the form of a white solid.
- HPLC (method 10): Rt=4.74 min;
- LC-MS (method 11): Rt=1.58 min; MS (ESIpos): m/z=905 (M+H)+.
- 16 mg (18 μmol) of this intermediate was dissolved in 1 mL dichloromethane, mixed with 0.2 mL trifluoroacetic acid and stirred for 30 min at RT. Then the mixture was concentrated in vacuo. The remaining residue was dried further in vacuo and then the dioxane was lyophilized, thus yielding 15.8 mg (97% of the theoretical) of the title compound.
- HPLC (method 10): Rt=2.66 min;
- LC-MS (method 1): Rt=1.03 min; MS (ESIpos): m/z=805 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3Z)-1,4-diphenylbut-3-en-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]-pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 7.1 mg (32 μmol) (2S,3Z)-1,4-diphenylbut-3-en-2-amine (intermediate 12).
- Yield: 9.2 mg (35% of the theoretical)
- HPLC (method 10): Rt=4.52 min;
- LC-MS (method 1): Rt=1.54 min; MS (ESIpos): m/z=891 (M+H)+.
- Then 9.5 mg (99% of the theoretical) of the title compound was obtained by subsequent cleavage of the Boc protective group with trifluoroacetic acid.
- HPLC (method 10): Rt=2.58 min;
- LC-MS (method 1): Rt=0.97 min; MS (ESIpos): m/z=791 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3E)-1,4-diphenylbut-3-en-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]-pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 7.1 mg (32 μmol) (2S,3E)-1,4-diphenylbut-3-en-2-amine (intermediate 13).
- Yield: 15.1 mg (58% of the theoretical)
- HPLC (method 10): Rt=4.2 min;
- LC-MS (method 1): Rt=1.51 min; MS (ESIpos): m/z=891 (M+H)+.
- Then 15.7 mg (99% of the theoretical) of the title compound was obtained by subsequent cleavage of the Boc protective group with trifluoroacetic acid.
- HPLC (method 10): Rt=2.62 min;
- LC-MS (method 1): Rt=0.97 min; MS (ESIpos): m/z=791 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-1-benzylsulfonyl)-3-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxo-propyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 9.3 mg (20 μmol) (2S)-1-(benzylsulfanyl)-3-phenylpropan-2-amine (intermediate 11).
- Yield: 19.2 mg (68% of the theoretical)
- HPLC (method 10): Rt=3.5 min;
- LC-MS (method 1): Rt=1.41 min; MS (ESIpos): m/z=957 (M+H)+.
- Then 19.3 mg (99% of the theoretical) of the title compound was obtained by subsequently splitting off the Boc protective group with trifluoroacetic acid.
- HPLC (method 10): Rt=2.52 min;
- LC-MS (method 1): Rt=0.86 min; MS (ESIpos): m/z=857 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 12.2 mg (32 μmol) (1S)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethanamine trifluoroacetic acid salt (intermediate 14).
- Yield: 22 mg (81% of the theoretical)
- HPLC (method 10): Rt=3.74 min;
- LC-MS (method 1): Rt=1.45 min; MS (ESIpos): m/z=933 (M+H)+.
- Then 22.4 mg (98% of the theoretical) of the title compound was obtained by subsequently splitting off the Boc protective group with trifluoroacetic acid.
- HPLC (method 10): Rt=2.52 min;
- LC-MS (method 1): Rt=0.85 min; MS (ESIpos): m/z=833 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 12.2 mg (32 μmol) (1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethanamine trifluoroacetic acid salt (intermediate 15).
- Yield: 17 mg (64% of the theoretical)
- HPLC (method 10): Rt=3.74 min;
- LC-MS (method 1): Rt=1.45 min; MS (ESIpos): m/z=933 (M+H)+.
- Then 17.1 mg (99% of the theoretical) of the title compound was obtained by subsequently splitting off the Boc protective group with trifluoroacetic acid.
- HPLC (method 10): Rt=2.55 min;
- LC-MS (method 11): Rt=0.85 min; MS (ESIpos): m/z=833 (M+H)+.
-
- First, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-{[(2S,3E)-4-[4-(methoxycarbonyl)phenyl]-1-phenylbut-3-en-2-yl}amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide was synthesized by analogy with the synthesis of intermediate 17 by reacting 20 mg (29 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) with 12.7 mg (32 μmol) methyl-4-[(1E,3S)-3-amino-4-phenylbut-1-en-1-yl]benzoate trifluoroacetic acid salt (intermediate 16).
- Yield: 8.8 mg (32% of the theoretical)
- LC-MS (method 1): Rt=1.53 min; MS (ESIpos): m/z=949 (M+H)+.
- Then 8 mg (90% of the theoretical) of the title compound was obtained by subsequently splitting off the Boc protective group with trifluoroacetic acid.
- LC-MS (method 1): Rt=1.00 min; MS (ESIpos): m/z=849 (M+H)+.
-
- 76 μL (438 μmol) N,N-diisopropylethylamine, 83 mg (219 μmol HATU and 26 mg (161 μmol) 2-(1H-indol-3-yl)ethanamine were added to a solution of 100 mg (146 μmol) N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{2S)-2-[(1R,2R)-2-carboxy-1-methoxypropyl]pyrrolidin-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (intermediate 7) in 30 mL DMF at RT. The mixture was stirred for 15 min at RT. Then the reaction mixture was concentrated in vacuo and the residue was separated into its components by preparative HPLC, yielding 101 mg (83% of the theoretical) of the Boc-protected intermediate, N-(tert-butoxycarbonyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[2-(1H-indoll-3-yl)ethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide.
- LC-MS (method 1): Rt=1.32 min; m/z=828 (M+H)+.
- 101 mg (122 μmol) of this intermediate was dissolved in 15 mL dichloromethane, mixed with 1 mL trifluoroacetic acid and stirred for 30 min at RT. Then the mixture was concentrated in vacuo and the remaining residue was lyophilized from water/acetonitrile, yielding 108 mg of the title compound in a quantitative yield as an almost colorless foam.
- LC-MS (method 1): Rt=0.84 min; MS (ESIpos): m/z=728 (M+H)+.
-
- The title compound was obtained by analogy with the synthesis of intermediate 24 in two steps, starting with 60 mg (88 μmol) of intermediate 7 by coupling with 10 mg (88 μmol) 2-phenylethanamine and then splitting off Boc using trifluoroacetic acid. this yielded 34 mg (97% of the theoretical) of the title compound.
- HPLC (method 5): Rt=2.71 min;
- LC-MS (method 1): Rt=0.80 min; MS (ESIpos): m/z=689 (M+H)±.
-
- 14.5 mg (16 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3Z)-1,5-diphenylpent-3-en-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 17) was dissolved in 1 mL dioxane/water (1:1) and mixed with 20.4 μL (32 μmol) of a 15% aqueous solution of 4-oxobutanoic acid. The batch was then stirred for one hour at 100° C. After cooling to RT, 1.1 mg (17 μmol) sodium cyanoborohydride was added and the mixture was adjusted to a pH of 3 by adding approx. 150 μL 0.1N hydrochloric acid. The batch was then stirred for two hours more at 100° C. Then 1.1 mg (17 μmol) sodium cyanoborohydride was added again and the mixture was next adjusted to a pH of 3 by adding approx. 300 μL 0.1N hydrochloric acid. The batch was then stirred again for two hours at 100° C. If the reaction was still incomplete, this procedure was repeated once more. Finally, the batch was concentrated and the raw product was purified by preparative HPLC and lyophilized from dioxane, thereby yielding 13.1 mg (93% of the theoretical) of the title compound in the form of a white solid.
- HPLC (method 10): Rt=2.63 min;
- LC-MS (method 1): Rt=1.01 min; MS (ESIpos): m/z=891 (M+H)+.
-
- 9 mg (10 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3Z)-1,4-diphenylbut-3-en-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 18) was dissolved in 0.6 mL dioxane/water (1:1) and reacted with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride in a process similar to the synthesis in Example 1. After lyophilization from dioxane, 5.6 mg (64% of the theoretical) of the title compound was obtained in the form of a white solid.
- HPLC (method 10): Rt=2.61 min;
- LC-MS (method 11): Rt=0.94 min; MS (ESIpos): m/z=877 (M+H)+.
- HR-MS (method 13): m/z=876.5.
-
- 15.5 mg (10 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S,3E)-1,4-diphenylbut-3-en-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 19) was dissolved in 1.0 mL dioxane/water (1:1) and reacted with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride, by analogy with the synthesis in Example 1. After lyophilization from dioxane, 10.3 mg (68% of the theoretical) of the title compound was obtained in the form of a white solid.
- HPLC (method 10): Rt=2.59 min;
- LC-MS (method 11): Rt=0.94 min; MS (ESIpos): m/z=877 (M+H)+.
- HR-MS (method 13): m/z=876.6;
- 1H-NMR (500 MHz, dichloromethane-d2): δ [ppm]=0.72-1.21 (m, 18H), 1.23-1.47 (m, 3H), 1.51-2.22 (m, 8H), 2.25-2.54 (m, 5H), 2.65-2.86 (m, 2H), 2.90-3.47 (m, 16H), 3.53-4.46 (m, 6H), 4.71-5.27 (m, 4H), 5.46-5.72 (m, 1H), 6.10-6.36 (m, 1H), 6.44-6.67 (m, 2H), 7.03-7.67 (m, 10H), 9.13 (br. s, 1H)
-
- 19.3 mg (20 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(2S)-1-(benzylsulfanyl)-3-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 20) was dissolved in 1.2 mL dioxane/water (1:1) and reacted with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride, by analogy with the synthesis in Example 1. After lyophilization from dioxane, 8.6 mg (45% of the theoretical) of the title compound was obtained in the form of a white solid.
- LC-MS (method 11): Rt=0.85 min; MS (ESIpos): m/z=943 (M+H)+.
- HR-MS (method 13): m/z=942.6;
- 1H-NMR (500 MHz, dichloromethane-d2): δ [ppm]=0.72-1.23 (m, 18H), 1.26-1.56 (m, 2H), 1.60-1.94 (m, 4H), 1.95-2.17 (m, 3H), 2.22-2.54 (m, 5H), 2.69-2.87 (m, 2H), 2.90-3.27 (m, 11H), 3.31-3.53 (m, 8H), 3.58-4.20 (m, 7H), 4.25-4.54 (m, 3H), 4.59-5.15 (m, 4H), 6.22 (br. s, 1H), 6.97-8.00 (m, 10H), 9.13 (br. s, 1H)
-
- 22.4 mg (24 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1S)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]-amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 21) was dissolved in 1.4 mL dioxane/water (1:1) and reacted with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride by analogy with the synthesis according to Example 1. After lyophilization from dioxane, 8.2 mg (38% of the theoretical) of the title compound was obtained in the form of a white solid.
- HPLC (method 10): Rt=2.54 min;
- LC-MS (method 1): Rt=0.94 min; MS (ESIpos): m/z=919 (M+H)+.
- HR-MS (method 13): m/z=918.6;
- 1H-NMR (500 MHz, dichloromethane-d2): δ [ppm]=0.58-1.21 (m, 20H), 1.25-1.52 (m, 2H), 1.62-2.19 (m, 8H), 2.28-2.50 (m, 5H), 2.64-2.84 (m, 2H), 2.89-3.16 (m, 6H), 3.19-3.52 (m, 10H), 3.59-4.00 (m, 4H), 4.02-4.40 (m, 3H), 4.66-5.13 (m, 3H), 5.61 (d, 1H), 7.32 (d, 5H), 7.49-7.69 (m, 3H), 7.93-8.16 (m, 2H), 9.07 (br. s, 1H).
-
- 17.1 mg (18 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-{[(1R)-2-phenyl-1-(5-phenyl-1,3,4-oxadiazol-2-yl)ethyl]-amino}propyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 22) was dissolved in 0.6 mL dioxane/water (1:1) and reacted with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride in a process similar to the synthesis process in Example 1. After lyophilization from dioxane, 14.8 mg (89% of the theoretical) of the title compound was obtained in the form of a white solid.
- HPLC (method 10): Rt=2.54 min;
- LC-MS (method 1): Rt=0.92 min; MS (ESIpos): m/z=919 (M+H)+.
-
- The title compound was synthesized by analogy with the synthesis process of Example 1 by reacting 100 mg (119 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[2-(1H-indol-3-yl)ethyl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 24) with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride.
- Yield: 50 mg (49% of the theoretical)
- LC-MS (method 1): Rt=0.87 min; MS (ESIpos): m/z=814 (M+H)+.
-
- The title compound was synthesized by analogy with the synthesis process of Example 1 by reacting 57 mg (71 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl}pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 25) with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride.
- Yield: 10 mg (19% of the theoretical)
- LC-MS (method 1): Rt=0.85 min; MS (ESIpos): m/z=775 (M+H)+.
-
- The title compound was synthesized by analogy with the synthesis process of Example 1 by reacting 57 mg (71 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]-pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt [synthesized like intermediate 17 by coupling intermediate 7 with (1S,2R)-(+)-norephedrine and then deprotecting it with trifluoroacetic acid] with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride.
- Yield: 94 mg (84% of the theoretical)
- LC-MS (method 1): Rt=0.79 min; MS (ESIpos): m/z=805 (M+H)+.
-
- The title compound was synthesized by analogy with the synthesis process of Example 1 by reacting 45 mg (47 μmol) N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-{[(2S,3E)-4-[4-(methoxycarbonyl)phenyl]-1-phenylbut-3-en-2-yl}amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide trifluoroacetic acid salt (intermediate 23) with a 15% aqueous solution of 4-oxobutanoic acid in the presence of sodium cyanoborohydride.
- Yield: 33.9 mg (78% of the theoretical)
- LC-MS (method 1): Rt=1.02 min; MS (ESIpos): m/z=933 (M+H)+.
-
- 33.9 mg (36 μmol) N-(3-carboxypropyl)-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-(1 (2S,3E)-4-[4-(methoxycarbonyl)phenyl]-1-phenylbut-3-en-2-yl}amino)-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-5-methyl-1-oxoheptan-4-yl]-N-methyl-L-valinamide (Example 10) was placed in 1.1 mL THF/water (1:1) and mixed with 3.5 mg (145 μmol) lithium hydroxide. The reaction mixture was stirred over night at RT, then acidified by adding 1N hydrochloric acid and extracted twice with 10 mL each time. The combined organic phases were dried over magnesium sulfate and concentrated, yielding 18.3 mg (84% purity, 46% of the theoretical) of the title compound.
- LC-MS (method 9): Rt=4.98 min; MS (ESIpos): m/z=919 (M+H)+.
- The biological activity of the compounds according to the invention can be demonstrated by in vitro and in vivo investigations, such as those with which those skilled in the art are familiar. For example, the pharmacological and pharmacokinetic properties of the compounds can according to the invention be determined with the help of the assays described below.
- A defined cell count of the human colon carcinoma cell line HT29 wt (wild type) was sown in a 96-well microtiter plate in whole medium (10% FCS-RPMI) (2500 cells/well) and incubated overnight at 37° C./5% CO2. After 18 hours, the inoculation medium was replaced by fresh medium with 10% FCS. The treatment started with addition of the respective test substance. Of the substances to be investigated, dose-effect curves were determined in a concentration range of 10−5 M to 10−14 M (1:10 dilution series). Incubation times of 48 h to 96 h were selected. Proliferation was detected with the help of the MTT assay (ATCC, Manassas, Va., USA, catalog no. 30-1010K). After the end of the selected incubation time, the MTT reagent was incubated with the cells for 4 h before lysis of the cells was performed overnight by adding the detergent. The dye that was formed was detected at 570 nm. The proliferation with otherwise identically treated cells but not with the test substance was defined as the 100% value. The data obtained from this test represents triple determinations, and at least two independent experiments were performed.
- The IC50 values of representative exemplary embodiments from this assay are listed in Table 1 below:
-
TABLE 1 Exemplary embodiment IC50 [nM] 1 15 2 3.3 3 0.3 4 1.1 5 0.1 6 0.1 8 0.5 9 6 11 4.5 - In comparison with this, monomethylauristatin F (MMAF) had an IC50 value of 10 nM in this test.
- Cancer cells are degenerate or neoplastic cells, which often lead to development of a tumor through increased cell division. Microtubules form the spindle fibers of the spindle apparatus and are an essential component of the cell cycle. Regulated buildup and breakdown of microtubule permit an accurate distribution of chromosomes to the daughter cells and represent a continuous dynamic process. A disturbance in these dynamics leads to faulty cell division and ultimately to cell death. However, the increased cell division of cancer cells makes them especially susceptible to spindle fiber toxins, which are a fixed component of chemotherapy. Spindle fiber toxins such as paclitaxel or epothilone lead to a greatly increased rate of polymerization of the microtubules, whereas vinca alkaloids or monomethylauristatin E (MMAE) will lead to a greatly reduced rate of polymerization of the microtubules. In both cases, the necessary dynamics of the cell cycle are sensitive to disturbance. The compounds investigated in the context of the present invention lead to a reduced rate of polymerization of the microtubules.
- The “Fluorescence-based Microtubule Polymerization Assay Kit” from the company Cytoskeleton (Denver, Colo., USA; order no. BK011) was used to investigate tubulin polymerization. In this assay, GTP is added to unpolymerized tubulin, so the polymerization can take place spontaneously. The assay is based on the binding of the fluorophore 4′,6-diamidino-2-phenylindole (DAPI) to tubulin. Free and bound DAPI can be differentiated on the basis of different emission spectra. DAPI has a much higher affinity for polymerized tubulin in comparison with unpolymerized tubulin, so tubulin polymerization can be tracked on the basis of the increase in the fluorescence of bound DAPI fluorophores.
- To perform this assay, the test substances dissolved in DMSO were diluted in water from their initial concentration of 10 mM to 1 μM. In addition to the buffer controls, polymerization-increasing paclitaxel and polymerization-inhibiting vinblastine were also included as assay controls. For the measurement, 96-well plates with a half bottom area were used, tracking the kinetics of the tubulin polymerization for one hour at 37° C. in a fluorimeter. The excitation wavelength was 355 nm, and the emission was tracked at 460 nm. For the range of the linear rise within the first 10 minutes, the change in fluorescence per minute (ΔF/min) was calculated, representing the rate of polymerization of the microtubules. The potency of the test substances was quantified on the basis of the respective reduction in the rate of polymerization.
- Of the respective test substance, 1 mg was dissolved in 0.5 mL acetonitrile/DMSO (9:1). Of this solution, 20 μL was removed and added to 1 mL rat plasma and human plasma at 37° C. (plasma of male Wistar rats with Li heparin, Harlan & Winkelmann and/or human leukocyte-depleted fresh plasma from whole blood specimens). Immediately after adding the specimen (initial value as reference variable) and then after 5, 10, 30, 60, 120, 180 and 240 minutes and optionally also after 24 hours, 100 μL aliquots were taken and added to 300 μL acetonitrile. The precipitated plasma proteins were centrifuged for 10 minutes at 5000 rpm, and then 30 μL of the supernatant was analyzed by HPLC to determine its unchanged test substance content. The results were quantified based on area percent of the corresponding peaks.
- Instrument: Agilent 1200 with DAD, binary pump, autosampler, column oven and thermostat; column: Kromasil 100 C18, 250 mm×4 mm, 5 μm; column temperature: 45° C.; eluent A: 5 mL perchloric acid/L water; eluent B: acetonitrile; gradient: 0-8 min 98% A, 2% B: 8-15 min 56% A, 44% B; 15-20 min 10% A, 90% B; 20-21 min 10% A, 90% B; 21-23 min 98% A, 2% B; 23-25 min 98% A, 2% B; flow rate: 2 mL/min; UV detection: 220 nm.
- Instrument: Agilent 1100 with DAD, binary pump, autosampler, column over and thermostat; column: Kromasil 100 C18, 250 mm×4 mm, 5 μm; column temperature: 45° C.; eluent A: 5 mL perchloric acid/L water; eluent B: acetonitrile; gradient: 0-3 min 98% A, 2% B; 3-10 min 65% A, 35% B; 10-15 min 40% A, 60% B; 15-21 min 10% A, 90% B; 21-22 min 10% A, 90% B; 22-24 min 98% A, 2% B; 24-26 min 98% A, 2% B; flow rate 2 mL/min; UV detection: 220 nm.
- The respective test substance was incubated in rat plasma and/or human plasma at 37° C. for a period of 5 h while stirring lightly. At various points in time (0, 2, 5, 10, 20, 30, 60, 120, 180 and 300 minutes), a 100 μL aliquot was taken. After adding an internal standard (10 μL), the proteins were precipitated by adding 200 μL and the mixture was centrifuged for 5 minutes in an Eppendorf centrifuge. After adding 150 μL ammonium acetate buffer, pH 3, to 150 μL of the supernatant, the unchanged test substance content was analyzed by LC/MSMS.
- The cell permeability of a substance can be analyzed by in vitro testing in a flux assay using Caco-2 cells [M. D. Troutman and D. R. Thakker, Pharm. Res. 20 (8), 1210-1224 (2003)]. To do so, the cells were cultured for 15-16 days on 24-hole filter plates. To determine the permeation, the respective test substance was applied to the cells either apically (A) or basally (B) in a HEPES buffer and incubated for 2 h. After 0 h and after 2 h, samples were taken from the cis- and trans-compartments. The samples were separated by HPLC (Agilent 1200, Böblingen, Germany) using reverse phase columns. The HPLC system was coupled via a turbo ion spray interface to an API 4000 triple quadrupole mass spectrometer (Applied Biosystems Applera, Darmstadt, Germany). The permeability was evaluated on the basis of a Papp value, which was calculated using the equation published by Schwab et al. [D. Schwab et al., J. Med. Chem. 46, 1717-1725 (2003)]. A substance was classified as being actively transported if the ratio of Papp (B−A) to Papp (A−B) was >2 or <0.5.
- The permeability of B to A [Papp (B−A)] is of crucial importance for toxophores that are released intracellularly. The lower this permeability, the longer is the dwell time of the substance in the cell after intracellular release and thus also the time available for an interaction with the biochemical target (here: tubulin).
- Table 2 below shows permeability data for representative exemplary embodiments from this assay:
-
TABLE 2 Exemplary embodiment Papp (B-A) [nm/s] 2 157 3 179 4 19 5 29 6 45 7 11 8 10 9 4.5 11 2 - In comparison with this, monomethylauristatin E (MMAE) and monomethylauristatin F (MMAF) had a Papp value of 89 nm/s or 73 nm/s, respectively, in this test.
- Many tumor cells express transporter proteins for active ingredients and drugs, which is often associated with development of a resistance to cytostatics. Substances that are not substrates of such transporter proteins, such as P-glycoprotein (P-gp) or BCRP could thus have an improved profile of effect.
- The substrate properties of a substance for P-gp (ABCB1) were determined by means of a flux assay using LLC-PK1 cells which overexpress P-gp (L-MDR1 cells) [A. H. Schinkel et al., J. Clin. Invest. 96, 1698-1705 (1995)]. To do so, the LLC-PK1 cells or L-MDR1 cells were cultured for 3-4 days on 96-well filter plates. To determine the permeation, the respective test substance, either alone or in the presence of an inhibitor (e.g., ivermectin or verapamil) in a HEPES buffer was applied to the cells either apically (A) or basally (B) and incubated for 2 h. After 0 h and after 2 h, samples were taken from the cis- and trans-compartments. The samples were separated by HPLC using reverse phase columns. The HPLC system was coupled via a turbo ion spray interface to an API 3000 triple quadrupole mass spectrometer (Applied Biosystems Applera, Darmstadt, Germany). The permeability was evaluated on the basis of a Papp value, which was calculated using the equation published by Schwab et al. [D. Schwab et al., J. Med. Chem. 46, 1716-1725 (2003)]. A substance was classified as being a P-gp substrate if the efflux ratio Papp (B−A) to Papp (A−B) was >2.
- The efflux ratios in L-MDR1 and LLC-PK1 cells or the efflux ratio in the presence or absence of an initiator can be compared with one another as additional criteria for evaluating the P-gp substrate properties. If these values differ by more than a factor of 2, then the respective substance is a P-gp substrate.
- The compounds according to the invention may be converted to pharmaceutical preparations by the following method:
- 100 mg of the compound according to the invention, 50 mg lactose (monohydrate), 50 mg cornstarch (native), 10 mg polyvinylpyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg magnesium stearate
- Tablet weight 212 mg; diameter 8 mm; radius of curvature 12 mm.
- The mixture of the compound according to the invention, lactose and starch is granulated with a 5% solution (w/w) of the PVP in water. The granules are mixed with the magnesium stearate for five minutes after drying. This mixture is pressed with a conventional tablet press (see above for the format of the tablet). A pressing force of 15 kN was used as the guideline value for pressing the tablets.
- 1000 mg of the compound according to the invention, 1000 mg ethanol (96%), 400 mg Rhodigel® (xanthan gum from FMC, Pennsylvania, USA) and 99 g water.
- 10 mL oral suspension corresponds to a single dose of 100 mg of the compound according to the invention.
- 500 mg of the compound according to the invention, 2.5 g polysorbate and 97 g polyethylene glycol 400.20 g of the oral solution corresponds to a single dose of 100 mg of the compound according to the invention.
- The compound according to the invention is suspended in the mixture of polyethylene glycol and polysorbate while stirring. The stirring process is continued until the compound according to the invention is completely dissolved.
- i.v. Solution:
- The compound according to the invention is dissolved in a concentration below the saturation solubility in a physiologically tolerable solvent (e.g., isotonic saline solution, glucose solution 5% and/or PEG 400 solution 30%). The solution is sterile filtered and bottled in sterile and pyrogen-free injection vials.
Claims (11)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11158481.9 | 2011-03-16 | ||
EP11158481 | 2011-03-16 | ||
EP11158481 | 2011-03-16 | ||
PCT/EP2012/054294 WO2012123423A1 (en) | 2011-03-16 | 2012-03-12 | N-carboxyalkyl-auristatins and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140080763A1 true US20140080763A1 (en) | 2014-03-20 |
US9029406B2 US9029406B2 (en) | 2015-05-12 |
Family
ID=45812791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/004,699 Active US9029406B2 (en) | 2011-03-16 | 2012-03-12 | N-carboxyalkylauristatins and use thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US9029406B2 (en) |
EP (1) | EP2686336B1 (en) |
JP (2) | JP6023097B2 (en) |
CN (1) | CN103764667B (en) |
CA (1) | CA2829736C (en) |
ES (1) | ES2543888T3 (en) |
HK (1) | HK1191034A1 (en) |
WO (1) | WO2012123423A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987209B2 (en) | 2010-09-29 | 2015-03-24 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatin and the use thereof |
US8992932B2 (en) | 2011-04-21 | 2015-03-31 | Seattle Genetics, Inc. | Binder-drug conjugates (ADCs) and use thereof |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
US10912841B2 (en) | 2014-04-25 | 2021-02-09 | Pierre Fabre Medicament | Antibody-drug-conjugate and its use for the treatment of cancer |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3327027T1 (en) | 2011-11-17 | 2021-03-31 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
FR3005051A1 (en) * | 2013-04-25 | 2014-10-31 | Pf Medicament | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINES |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
MX2016007865A (en) | 2013-12-17 | 2017-01-11 | Novartis Ag | Cytotoxic peptides and conjugates thereof. |
EP3086815B1 (en) | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
RU2692563C2 (en) | 2014-04-25 | 2019-06-25 | Пьер Фабр Медикамент | Conjugate of anti-igf-1r antibody with drug and use thereof for treating cancer |
CN106573956A (en) | 2014-06-13 | 2017-04-19 | 诺华股份有限公司 | Auristatin derivatives and conjugates thereof |
CN111393346B (en) * | 2020-06-02 | 2020-08-25 | 凯莱英生命科学技术(天津)有限公司 | Synthesis method of N-Boc-Dolaprine and Boc-Dap DCHA |
WO2023033129A1 (en) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | Pharmaceutical composition for treating and/or preventing cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
EP1045858B1 (en) | 1998-01-09 | 2004-12-08 | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY | Anti-cryptococcal peptides |
CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6737409B2 (en) * | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
HUE027549T2 (en) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
US8288352B2 (en) | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
AU2006269422B2 (en) | 2005-07-07 | 2012-12-06 | Seagen Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
PT2061814E (en) | 2006-10-27 | 2012-09-10 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
DK2265283T3 (en) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin drug linker conjugates |
ES2528956T3 (en) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | New derivatives of auristatin and its use |
EP2621508B1 (en) * | 2010-09-29 | 2015-08-26 | Seattle Genetics, Inc. | N-carboxyalkyl auristatins and the use thereof |
KR102023496B1 (en) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | Novel binder-drug conjugates (ADCs) and their use |
-
2012
- 2012-03-12 CN CN201280019732.4A patent/CN103764667B/en active Active
- 2012-03-12 EP EP12708034.9A patent/EP2686336B1/en active Active
- 2012-03-12 ES ES12708034.9T patent/ES2543888T3/en active Active
- 2012-03-12 WO PCT/EP2012/054294 patent/WO2012123423A1/en active Application Filing
- 2012-03-12 US US14/004,699 patent/US9029406B2/en active Active
- 2012-03-12 JP JP2013558400A patent/JP6023097B2/en active Active
- 2012-03-12 CA CA2829736A patent/CA2829736C/en active Active
-
2014
- 2014-05-07 HK HK14104335.0A patent/HK1191034A1/en unknown
-
2016
- 2016-07-25 JP JP2016145282A patent/JP2016185987A/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
Hörig et al., J. Translational Med. 2:44 (2004). * |
Vallianou, N., et al., Anti-Cancer Agents in Medicinal Chemistry, 14:706 (2014) Abstract only. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8987209B2 (en) | 2010-09-29 | 2015-03-24 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatin and the use thereof |
US8992932B2 (en) | 2011-04-21 | 2015-03-31 | Seattle Genetics, Inc. | Binder-drug conjugates (ADCs) and use thereof |
US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
US10912841B2 (en) | 2014-04-25 | 2021-02-09 | Pierre Fabre Medicament | Antibody-drug-conjugate and its use for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
JP2016185987A (en) | 2016-10-27 |
JP2014515735A (en) | 2014-07-03 |
WO2012123423A1 (en) | 2012-09-20 |
CN103764667B (en) | 2017-06-20 |
HK1191034A1 (en) | 2014-07-18 |
CA2829736A1 (en) | 2012-09-20 |
JP6023097B2 (en) | 2016-11-09 |
ES2543888T3 (en) | 2015-08-25 |
US9029406B2 (en) | 2015-05-12 |
CA2829736C (en) | 2020-07-21 |
CN103764667A (en) | 2014-04-30 |
EP2686336A1 (en) | 2014-01-22 |
EP2686336B1 (en) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9029406B2 (en) | N-carboxyalkylauristatins and use thereof | |
US8722629B2 (en) | Auristatin derivatives and use thereof | |
US8987209B2 (en) | N-carboxyalkyl-auristatin and the use thereof | |
AU2017203928B2 (en) | Novel binder-drug conjugates (ADCs) and their use | |
EP2790731A2 (en) | Fgfr-binder-active agent conjugates | |
TW201339175A (en) | New binder-drug conjugates (ADCs) and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER INTELLECTURAL PROPERTY GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LERCHEN, HANS-GEORG;EL SHEIKH, SHERIF;STELTE-LUDWIG, BEATRIX;AND OTHERS;SIGNING DATES FROM 20121107 TO 20121210;REEL/FRAME:031191/0113 Owner name: SEATTLE GENETICS, INC., WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER INTELLECTURAL PROPERTY GMBH;REEL/FRAME:031191/0245 Effective date: 20121107 |
|
AS | Assignment |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, GERMANY Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 031191 FRAME 0113. ASSIGNOR(S) HEREBY CONFIRMS THE BAYER INTELLECTUAL PROPERTY GMBH;ASSIGNORS:LERCHEN, HANS-GEORG;EL SHEIKH, SHERIF;STELTE-LUDWIG, BEATRIX;AND OTHERS;SIGNING DATES FROM 20121107 TO 20121210;REEL/FRAME:031674/0931 Owner name: SEATTLE GENETICS, INC., WASHINGTON Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME AND ASSIGNEE CITY ADDRESS PREVIOUSLY RECORDED ON REEL 013391 FRAME 0245. ASSIGNOR(S) HEREBY CONFIRMS THE BAYER INTELLECTUAL PROPERTY GMBH; ASSIGNEE CITY ADDRESS SHOULD READ: BOTHELL;ASSIGNOR:BAYER INTELLECTUAL PROPERTY GMBH;REEL/FRAME:031674/0992 Effective date: 20121107 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: SEAGEN INC., WASHINGTON Free format text: CHANGE OF NAME;ASSIGNOR:SEATTLE GENETICS, INC.;REEL/FRAME:055362/0182 Effective date: 20201006 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |